<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">91040</article-id><article-id pub-id-type="doi">10.7554/eLife.91040</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.91040.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Purine nucleosides replace cAMP in allosteric regulation of PKA in trypanosomatid pathogens</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-316821"><name><surname>Ober</surname><given-names>Veronica Teresa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8631-9255</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-328341"><name><surname>Githure</surname><given-names>George Boniface</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-317080"><name><surname>Volpato Santos</surname><given-names>Yuri</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9545-8430</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-328343"><name><surname>Becker</surname><given-names>Sidney</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4746-2822</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-328342"><name><surname>Moya Munoz</surname><given-names>Gabriel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-100664"><name><surname>Basquin</surname><given-names>Jérôme</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-316947"><name><surname>Schwede</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-100009"><name><surname>Lorentzen</surname><given-names>Esben</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6493-7220</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-58700"><name><surname>Boshart</surname><given-names>Michael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5070-2663</contrib-id><email>boshart@lmu.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05591te55</institution-id><institution>Faculty of Biology, Genetics, Ludwig-Maximilians University Munich (LMU)</institution></institution-wrap><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vpj4s62</institution-id><institution>Max Planck Institute of Molecular Physiology</institution></institution-wrap><addr-line><named-content content-type="city">Dortmund</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution>TU Dortmund, Department of Chemistry and Chemical Biology</institution><addr-line><named-content content-type="city">Dortmund</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04py35477</institution-id><institution>Max Planck Institute for Biochemistry</institution></institution-wrap><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution>BIOLOG Life Science Institute GmbH &amp; Co KG</institution><addr-line><named-content content-type="city">Bremen</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040r8fr65</institution-id><institution>Department of Molecular Biology and Genetics, Aarhus University</institution></institution-wrap><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>22</day><month>03</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP91040</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-28"><day>28</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-24"><day>24</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.24.563761"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-20"><day>20</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91040.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-02-20"><day>20</day><month>02</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91040.2"/></event></pub-history><permissions><copyright-statement>© 2023, Ober, Githure, Volpato Santos et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Ober, Githure, Volpato Santos et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-91040-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-91040-figures-v1.pdf"/><abstract><p>Cyclic nucleotide binding domains (CNB) confer allosteric regulation by cAMP or cGMP to many signaling proteins, including PKA and PKG. PKA of phylogenetically distant <italic>Trypanosoma</italic> is the first exception as it is cyclic nucleotide-independent and responsive to nucleoside analogues (Bachmaier et al., 2019). Here, we show that natural nucleosides inosine, guanosine and adenosine are nanomolar affinity CNB ligands and activators of PKA orthologs of the important tropical pathogens <italic>Trypanosoma brucei</italic>, <italic>Trypanosoma cruzi,</italic> and <italic>Leishmania</italic>. The sequence and structural determinants of binding affinity, -specificity and kinase activation of PKAR were established by structure-activity relationship (SAR) analysis, co-crystal structures and mutagenesis. Substitution of two to three amino acids in the binding sites is sufficient for conversion of CNB domains from nucleoside to cyclic nucleotide specificity. In addition, a trypanosomatid-specific C-terminal helix (αD) is required for high affinity binding to CNB-B. The αD helix functions as a lid of the binding site that shields ligands from solvent. Selectivity of guanosine for CNB-B and of adenosine for CNB-A results in synergistic kinase activation at low nanomolar concentration. PKA pulldown from rapid lysis establishes guanosine as the predominant ligand in vivo in <italic>T. brucei</italic> bloodstream forms, whereas guanosine and adenosine seem to synergize in the procyclic developmental stage in the insect vector. We discuss the versatile use of CNB domains in evolution and recruitment of PKA for novel nucleoside-mediated signaling.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>protein kinase A</kwd><kwd>nucleoside</kwd><kwd>cAMP</kwd><kwd>CNB domain</kwd><kwd>Trypanosoma</kwd><kwd>Leishmania</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002347</institution-id><institution>Bundesministerium für Bildung und Forschung</institution></institution-wrap></funding-source><award-id>grant reference 16GW0281-3</award-id><principal-award-recipient><name><surname>Schwede</surname><given-names>Frank</given-names></name><name><surname>Boshart</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003593</institution-id><institution>Conselho Nacional de Desenvolvimento Científico e Tecnológico</institution></institution-wrap></funding-source><award-id>PhD fellowship</award-id><principal-award-recipient><name><surname>Volpato Santos</surname><given-names>Yuri</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>BO1100/7-1</award-id><principal-award-recipient><name><surname>Boshart</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Brazilian Science Without Borders/CNPq program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Volpato Santos</surname><given-names>Yuri</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Life Sciences Munich Graduate School</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Volpato Santos</surname><given-names>Yuri</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A minimal subset of two to three residues in cyclic nucleotide binding (CNB) domains controls nucleoside vs. cyclic nucleotide specificity, repurposing PKA of certain pathogens for novel nucleoside signaling pathways or sensing.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Protein kinase A (PKA) is a prototype kinase first purified from rabbit skeletal muscle in 1968 (<xref ref-type="bibr" rid="bib103">Walsh et al., 1968</xref>). More than 40 years of trailblazing biochemical and structural work elucidated the mechanism of allosteric activation by cAMP, providing a paradigm of allosteric regulation (<xref ref-type="bibr" rid="bib96">Taylor et al., 2021</xref>). Inactive PKA is a dimeric or tetrameric complex of regulatory (R) and catalytic (C) subunits, depending on the species. Upon activation, two molecules of cAMP bind to two cyclic nucleotide binding domains (CNB) arranged in tandem in the C-terminal part of the regulatory subunit(s). Cyclic AMP binding to the C-terminal CNB-B initiates a conformation change that opens up the adjacent CNB-A for a second cAMP molecule whose binding completes the conformational transition that liberates the C-subunit from the holoenzyme complex (<xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>). The free C subunit is thereby released from autoinhibition and activated (<xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>; <xref ref-type="bibr" rid="bib95">Taylor et al., 2012</xref>). PKA is a highly conserved kinase present in all eukaryotes except plants, functioning in diverse signaling processes ranging from metabolic regulation and hormone action to cell differentiation and synaptic long-term potentiation underlying memory (<xref ref-type="bibr" rid="bib62">Lee et al., 2021</xref>). In protists and fungi, the predominant functions are response to carbon source changes and regulation of developmental transitions, infectivity, or sexual dimorphism (<xref ref-type="bibr" rid="bib83">Perrin et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Hitz et al., 2021</xref>; <xref ref-type="bibr" rid="bib100">Uboldi et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Jia et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Choi et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Kim et al., 2021</xref>; <xref ref-type="bibr" rid="bib102">Vaidyanathan et al., 2014</xref>). Regulation of PKA by cAMP was universally found (<xref ref-type="bibr" rid="bib86">Rinaldi et al., 2010</xref>; <xref ref-type="bibr" rid="bib41">Haste et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Kurokawa et al., 2011</xref>; <xref ref-type="bibr" rid="bib95">Taylor et al., 2012</xref>), which is why PKA and cAMP-dependent protein kinase are used as synonyms. Furthermore, cAMP dependence was assumed and widely cited in reviews for PKAs of species for which uncontested biochemical evidence is lacking, including protozoan flagellates of the phylogenetically distant order <italic>Kinetoplastida</italic>. It was therefore of greatest interest that PKA in <italic>Trypanosoma brucei</italic>, a parasitic and pathogenic member of the <italic>Kinetoplastida</italic> was found unresponsive to cAMP even at high intracellular concentrations (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Bubis et al., 2018</xref>). Compound screening then identified 7-deazapurine nucleoside antibiotics as nanomolar activators of PKA in <italic>T. brucei</italic> (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>).</p><p><italic>T. brucei</italic>, <italic>Trypanosoma cruzi,</italic> and <italic>Leishmania</italic> sp. are related trypanosomatid pathogens causing the deadly neglected tropical diseases sleeping sickness, Chagas disease and leishmaniosis, respectively. In addition, <italic>Trypanosoma</italic> is responsible as animal pathogen for important economic losses and impedes social development in affected countries. These organisms are famous for discovery of many exotic biochemical and genetic mechanisms (<xref ref-type="bibr" rid="bib69">Matthews, 2015</xref>), and not surprisingly, signaling systems diverge from other model organisms and few pathways are on the way to be assembled (<xref ref-type="bibr" rid="bib70">Matthews, 2021</xref>). Nevertheless, cAMP seems to play an important role: <italic>T. brucei</italic> encodes &gt;80 adenylate cyclase genes (<xref ref-type="bibr" rid="bib87">Salmon et al., 2012a</xref>) that are important for host innate immunity subversion (<xref ref-type="bibr" rid="bib88">Salmon et al., 2012b</xref>) and for development of the parasite in its insect vector (<xref ref-type="bibr" rid="bib6">Bachmaier et al., 2022</xref>). These pathways are obviously uncoupled from the cAMP unresponsive PKA and seem to use alternative and novel cAMP effectors (<xref ref-type="bibr" rid="bib7">Bachmaier et al., 2023</xref>). PKA in these parasites is essential and important for cell division (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Baker et al., 2021</xref>; <xref ref-type="bibr" rid="bib24">Cayla et al., 2022</xref>). In <italic>T. brucei,</italic> PKA has been identified as candidate member of a quorum sensing pathway and implicated in stage development (<xref ref-type="bibr" rid="bib74">Mony et al., 2014</xref>; <xref ref-type="bibr" rid="bib97">Toh et al., 2021</xref>). The genome of <italic>T. brucei</italic> encodes one regulatory and three catalytic subunits that all have syntenic orthologs in <italic>T. cruzi</italic> and <italic>Leishmania</italic>. The upstream pathway(s) regulating PKA in these organisms have not been identified. However, the high degree of conservation of the CNBs in TbPKA and their high affinity binding to nucleoside analogues (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>) suggested the existence of an alternative second messenger. PKG, a related AGC kinase, is also subject to allosteric regulation by cyclic nucleotides, responding to cyclic guanosine monophosphate (cGMP) instead of cAMP (<xref ref-type="bibr" rid="bib49">Huang et al., 2014b</xref>; <xref ref-type="bibr" rid="bib60">Kim and Sharma, 2021</xref>). The high structural similarity of the CNB domains in PKA and PKG spurred attempts to define determinants of cyclic nucleotide binding selectivity. Amino acids that contribute to selectivity have been identified (<xref ref-type="bibr" rid="bib66">Lorenz et al., 2017a</xref>; <xref ref-type="bibr" rid="bib92">Shabb et al., 1991</xref>; <xref ref-type="bibr" rid="bib91">Shabb et al., 1990</xref>; <xref ref-type="bibr" rid="bib48">Huang et al., 2014a</xref>; <xref ref-type="bibr" rid="bib105">Weber et al., 1989</xref>; <xref ref-type="bibr" rid="bib27">Corbin et al., 1986</xref>; <xref ref-type="bibr" rid="bib60">Kim and Sharma, 2021</xref>; <xref ref-type="bibr" rid="bib66">Lorenz et al., 2017a</xref>), but establishing a consensus of key determinants has been challenging. Differences in ligand specificity of PKAR between a pathogen and its host provides an opportunity for much needed drug development to fight neglected vector borne diseases caused by <italic>Trypanosomatida</italic>. Hence, identification of physiological ligands of trypanosomatid PKA and definition of their binding selectivity were important goals.</p><p>Here, we show that purine nucleosides exhibit nanomolar affinity for the PKA regulatory subunits of these pathogens and activate the kinases. We define the minimal changes that convert a nucleoside-specific CNB to cyclic nucleotide specificity. Furthermore, we see site-selective binding and synergy between guanosine and adenosine, compatible with binding in vivo to PKAR. Expansion of the ligand portfolio of CNBs in evolution has enabled repurposing of PKA for a different signaling pathway, while maintaining the sophisticated allosteric activation mechanism triggered by ligand binding to PKA.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Nucleosides are direct activators of PKA in trypanosomes</title><p>We recently identified the nucleoside analogue 7-cyano-7-deaza-inosine (7-CN-7-C-Ino, Jaspamycin) and related compounds like Toyocamycin as potent activators of the cAMP-independent PKA of <italic>Trypanosoma</italic> (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>). Attempts to bioinformatically detect pathways for synthesis of these nucleoside antibiotics in trypanosomatids have been unsuccessful. Therefore, we considered unmodified purine nucleosides and studied the structure-activity-relationship (SAR) for kinase activation (<xref ref-type="fig" rid="fig1">Figure 1a</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). Tagged R- and C1-subunits of <italic>T. brucei</italic> PKA were co-expressed in <italic>Leishmania tarentolae</italic> and stoichiometric holoenzyme complexes were tandem-affinity purified (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). The tandem-affinity purification to near homogeneity guaranteed removal of any heterologous complexes formed with endogenous PKA subunits of the expression system. EC<sub>50</sub> values for kinase activation were determined from dose response assays (<xref ref-type="fig" rid="fig1">Figure 1b</xref>, <xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). Surprisingly, inosine was the most potent activator (EC<sub>50</sub> 14 nM). We did not expect this result as the structure of TcPKAR bound to 7-CN-7-C-Ino (PDB: 6FTF) and computational docking of 7-deaza analogues had suggested an important role of the cyano group at position 7 of the purine ring (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>). The SAR analysis (<xref ref-type="fig" rid="fig1">Figure 1a</xref>, <xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>) showed the oxygen at position 6 in the purine ring to be particularly important, as nebularine, lacking a 6-substitution, was 186-fold less potent than inosine. An amino group substitution at position 6 (adenosine) resulted in a further twofold drop in potency. An amino group at position 2 (guanosine) caused 11-fold and a keto group in this position (xanthosine) a &gt;4400-fold lower activation potency, respectively. A structural isomer of inosine (allopurinol riboside) with restricted delocalized π-electron system showed 120-fold reduced activation. The structure of TcPKAR bound to 7-CN-7-C-Ino (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>) predicted an important role of the ribose moiety that is accommodated deep in the binding pocket. The 2´-, 3´- and 5´-deoxy derivatives of adenosine confirmed essential roles for all three hydroxyl groups of the ribose ring (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). Inosine and guanosine 5´-monophosphates were &gt;7700-fold less potent than the respective nucleosides and AMP did not activate even at 5 mM. Cyclic GMP activated the kinase in the upper micromolar range, whereas cAMP and cIMP were inactive up to 5 mM. Pyrimidine nucleosides uridine and cytidine were 3–4 orders of magnitude less potent than purine nucleosides (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). In summary, the natural nucleoside inosine is only twofold less potent as activator of TbPKAR than the nucleoside analogue activator 7-CN-7-C-Ino (6.5 nM; <xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>) but fivefold more potent than cAMP activation of the recombinant mammalian PKARIα2-2PKACα holoenzyme purified from <italic>Escherichia coli</italic> (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Therefore, purine nucleosides qualify as possible physiological activators of TbPKA in trypanosomes.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Trypanosomatid PKA binds to and is selectively activated by purine nucleosides.</title><p>(<bold>a</bold>) Structure-activity relationship (SAR) analysis for TbPKA kinase activation by nucleoside derivatives. Chemical structures and the corresponding EC<sub>50</sub> values are taken from <xref ref-type="table" rid="table1">Table 1</xref>. For representative dose-response curves see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. (<bold>b</bold>) Representative dose-response curves for activation of <italic>T. brucei</italic> PKAR-PKAC1 holoenzyme by inosine, guanosine or adenosine (in vitro kinase assay, n≥3 biological replicates). The calculated EC<sub>50</sub> values are displayed next to the graph and in <xref ref-type="table" rid="table1">Table 1</xref>, error bars indicate SD of technical triplicates. Purity of PKA enzymes is shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>. (<bold>c</bold>) Representative dose-response curves for activation of <italic>L. donovani</italic>, <italic>T. cruzi</italic> and mammalian (human RIα/mouse Cα) holoenzymes by purine nucleosides and cAMP, as in A. The calculated EC<sub>50</sub> values are displayed next to the curve and in <xref ref-type="table" rid="table1">Table 1</xref>, error bars indicate SD of technical triplicates; Purity of PKA holoenzyme is shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b, c</xref>. (<bold>d</bold>) Binding isotherms (ITC) of nucleoside-depleted (APO) <italic>T. brucei</italic> PKAR(199-499) upon titration with purine nucleosides. The graphs give the difference power (DP) between the reference and sample cells upon ligand injection as a function of time (upper panel). In the lower panel, the total heat exchange per mole of injectant (integrated peak areas from upper panel) is plotted against the molar ratio of ligand to protein. A representative curve out of ≥3 independent replicates is shown. The final given K<sub>D</sub> (as in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) was calculated as the mean (± SD) of at least three independent experiment (see source data files). For purity of R subunit eluted from SEC see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a, b</xref>. (<bold>e</bold>) Binding isotherms (ITC) of nucleoside-depleted (APO) <italic>L. donovani</italic> PKAR1(200–502) upon titration with purine nucleosides, as in D. Purity, aggregation state and thermal stability of protein sample prior to binding assays is shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c, d</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>In vitro kinase activation assays of <italic>T.</italic> <italic>brucei</italic> PKAR-PKAC1 holoenzyme by inosine, guanosine, or adenosine.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>In vitro kinase activation assays of <italic>T.</italic><italic>cruzi</italic> PKAR-PKAC2, <italic>L. donovani</italic> PKAR1-PKAC1 by inosine or cAMP (no activation) and of <italic>H. sapiens</italic> PKARIα-PKAC holoenzyme by inosine, guanosine, and adenosine (no activation) or cAMP.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>ITC measurements for inosine, guanosine or adenosine titrated to nucleoside-depleted (APO) <italic>T.</italic> <italic>brucei</italic> PKAR(199-499).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>ITC measurements for inosine, guanosine or adenosine titrated to nucleoside-depleted (APO) <italic>L</italic>. <italic>donovani</italic> PKAR1(200–502).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-data4-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Kinetoplastid PKA activation.</title><p>(<bold>a</bold>) Representative dose-response curves for activation of <italic>T. brucei</italic> PKAR-PKAC1 holoenzyme by compounds (structural formula of some in <xref ref-type="fig" rid="fig1">Figure 1a</xref>). The calculated EC<sub>50</sub> values (taken from <xref ref-type="table" rid="table1">Table 1</xref>) are displayed next to the curve, error bars indicate SD of technical triplicates. Purity of recombinant TbPKA (6xHis-TbPKAR/strep-TbPKAC1) was confirmed by SDS-PAGE (left). (<bold>b, c</bold>) as in A for LdPKA (6xHis-LdPKAR1/strep-LdPKAC1) and TcPKA (6xHis-TcPKAR/strep-TcPKAC2). Purity of recombinant proteins was confirmed by SDS-PAGE (left). (<bold>d</bold>) Binding isotherms of refolded APO <italic>H. sapiens</italic> PKARIα(1-381) in response to cAMP (left) and inosine (centre). On the right, binding isotherm for <italic>L. donovani</italic> PKAR1(200–502) in response to cAMP. Data representation as in <xref ref-type="fig" rid="fig1">Figure 1d</xref>, the calculated K<sub>D</sub> value for <italic>H. sapiens</italic> PKARIα(1-381) binding of cAMP (mean ± SD) is taken from .</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original Coomassie stained gels of tandem affinity purification of <italic>T</italic>.<italic>cruzi</italic> PKAR-PKAC2, <italic>L. donovani</italic> PKAR1-PKAC1and <italic>T. brucei</italic> PKAR-PKAC1.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91040-fig1-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Original Coomassie stained gels of tandem affinity purification of <italic>T</italic>.<italic>cruzi</italic> PKAR-PKAC2, <italic>L. donovani</italic> PKAR1-PKAC1and <italic>T. brucei</italic> PKAR-PKAC1 (labelled).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91040-fig1-figsupp1-data2-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>In vitro kinase activation assays of <italic>T.</italic> <italic>brucei</italic> PKAR-PKAC1 holoenzyme by compounds.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-figsupp1-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata4"><label>Figure 1—figure supplement 1—source data 4.</label><caption><title>In vitro kinase activation assays of <italic>L</italic>. <italic>donovani</italic> PKAR1-PKAC1 by guanosine and adenosine.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-figsupp1-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata5"><label>Figure 1—figure supplement 1—source data 5.</label><caption><title>In vitro kinase assays for activation of <italic>T</italic>. <italic>cruzi</italic> PKAR-PKAC2 by guanosine and adenosine.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-figsupp1-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata6"><label>Figure 1—figure supplement 1—source data 6.</label><caption><title>ITC measurement of cAMP titrated to <italic>H</italic>.<italic>sapiens</italic> PKARIα or <italic>L. donovani</italic> PKAR1(200–502).</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig1-figsupp1-data6-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Mass spectrometry identification of ligands bound to recombinant PKAR.</title><p>(<bold>a</bold>) Coomassie staining and quantification relative to a BSA standard of purified 6xHis-TbPKAR (TbR, 800 μg) and <italic>H. sapiens</italic> 6xHis-PKARIα (hRIα, 2400 μg) expressed in <italic>E. coli</italic>. (<bold>b</bold>) Proteins from A were boiled in MS grade H<sub>2</sub>O to release bound ligands and supernatants were tested for activation of mammalian PKAIα (left) and <italic>T. brucei</italic> PKA (right): (<bold>I</bold>) basal kinase activity (buffer control) (II) supernatant from mock purification from <italic>E. coli</italic> harboring an empty vector (III) supernatant from boiled hRIα (IV) supernatant from boiled TbPKAR (<bold>V</bold>) 10 μM of positive control ligand: inosine for TbPKA holoenzyme and cAMP for human PKAIα holoenzyme. (<bold>c</bold>) UV chromatogram (260 nm) from high-resolution HPLC-MS analysis of ligands from ≈ 3 nmoles of boiled TbPKAR. The amounts of inosine (16.57) and guanosine (17.19) are indicated next to the respective peak in the UV. Quantification has been performed by UV signal integration according to a standard curve. Amounts of adenosine were below the range of reliable UV quantification. (<bold>d</bold>) As in C for ligands released from human RIα; only cAMP was identified without quantification. (<bold>e</bold>) MS chromatogram from the HPLC-MS analysis described in c and d. The selected mass range ([M + H<sup>+</sup>]+/-0.003 m/z) for inosine, guanosine, adenosine and cAMP is individually presented (from left to right) as indicated. The retention time (Rt) is given for each identified peak.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Original Coomassie stained gel.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91040-fig1-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s2sdata2"><label>Figure 1—figure supplement 2—source data 2.</label><caption><title>Original Coomassie stained gel (labelled).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91040-fig1-figsupp2-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Thermodynamic signatures of ligand binding from ITC experiments.</title><p>Direct comparison of the thermodynamic signatures from all ITC experiments summarized in . Binding enthalpy is shown in green (ΔH), Gibbs free energy in blue (ΔG) and entropy in red (-TΔS).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig1-figsupp3-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Structure activity relation (SAR) analysis for PKA holoenzyme activation.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">PKA holoenzyme complex</th><th align="left" valign="bottom">Ligand</th><th align="left" valign="bottom">EC<sub>50</sub> (95% Cl)<sup><xref ref-type="table-fn" rid="table1fn1">*</xref></sup></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="17"><italic>T. brucei</italic> PKAR/PKAC1</td><td align="left" valign="bottom">Inosine</td><td align="left" valign="bottom">14 (13–15) nM</td></tr><tr><td align="left" valign="bottom">Guanosine</td><td align="left" valign="bottom">152 (132–172) nM</td></tr><tr><td align="left" valign="bottom">Adenosine</td><td align="left" valign="bottom">7.0 (6.9–8.4) µM</td></tr><tr><td align="left" valign="bottom">cAMP</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">cGMP</td><td align="left" valign="bottom">0.36 (0.33–0.41) mM</td></tr><tr><td align="left" valign="bottom">cIMP</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">AMP</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">GMP</td><td align="left" valign="bottom">1.1 (0.9–1.3) mM</td></tr><tr><td align="left" valign="bottom">IMP</td><td align="left" valign="bottom">108 (83–135) µM</td></tr><tr><td align="left" valign="bottom">2'-deoxyadenosine</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">3'-deoxyadenosine</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">5'-deoxyadenosine</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">Nebularine</td><td align="left" valign="bottom">2.6 (2.2–3.2) µM</td></tr><tr><td align="left" valign="bottom">Allopurinol riboside</td><td align="left" valign="bottom">1.7 (1.5–1.9) µM</td></tr><tr><td align="left" valign="bottom">Xanthosine</td><td align="left" valign="bottom">62 (51–72) µM</td></tr><tr><td align="left" valign="bottom">Uridine</td><td align="left" valign="bottom">40 (35–47) µM</td></tr><tr><td align="left" valign="bottom">Cytidine</td><td align="left" valign="bottom">≥350 µM</td></tr><tr><td align="left" valign="middle" rowspan="4"><italic>Leishmania</italic> PKAR1/PKAC1</td><td align="left" valign="bottom">Inosine</td><td align="left" valign="bottom">47 (33–63) nM</td></tr><tr><td align="left" valign="bottom">Guanosine</td><td align="left" valign="bottom">1.7 (1.4–2.1) µM</td></tr><tr><td align="left" valign="bottom">Adenosine</td><td align="left" valign="bottom">6.5 (5.7–7.6) µM</td></tr><tr><td align="left" valign="bottom">cAMP</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="middle" rowspan="4"><italic>T. cruzi</italic> PKAR/PKAC2</td><td align="left" valign="bottom">Inosine</td><td align="left" valign="bottom">150 (110–200) nM</td></tr><tr><td align="left" valign="bottom">Guanosine</td><td align="left" valign="bottom">3.5 (2.8–4.5) µM</td></tr><tr><td align="left" valign="bottom">Adenosine</td><td align="left" valign="bottom">8.3 (5.2–12.4) µM</td></tr><tr><td align="left" valign="bottom">cAMP</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="middle" rowspan="4">human RIα/mouse Cα</td><td align="left" valign="bottom">Inosine</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">Guanosine</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">Adenosine</td><td align="left" valign="bottom"><bold>-<sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">cAMP</td><td align="left" valign="bottom">75 (59–93) nM</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Mean half activation constants (EC<sub>50</sub>) and 95% confidence interval (95% CI) determined from <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> using Graphpad prism 7.0 for technical triplicates.</p></fn><fn id="table1fn2"><label>†</label><p>No activation was detected up to a maximum concentration of 5 mM.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Nucleoside activation of PKA in kinetoplastid pathogens</title><p>Next, we asked if activation by nucleosides and complete insensitivity to cAMP is a unique feature of <italic>T. brucei</italic> PKA or a shared feature in the protozoan class of Kinetoplastida. We selected the medically important <italic>T. cruzi</italic> and <italic>Leishmania donovani</italic> as representatives of this group. Orthologous regulatory subunits (TcPKAR and LdPKAR1) and catalytic subunits (TcPKAC2 and LdPKAC1), respectively, were tagged and co-expressed in <italic>L. tarentolae</italic>, and holoenzyme complexes were tandem affinity purified (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b, c</xref>). The kinase assay dose responses (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b, c</xref>,) show that inosine is the most potent of the tested nucleosides for all analysed species, whereas no activation was observed with cAMP, even at very high concentrations (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Activation potency of inosine or guanosine was between threefold and 23-fold lower for <italic>Leishmania</italic> and <italic>T. cruzi</italic>, compared to <italic>T. brucei</italic>. The mammalian RIα2:Cα2 holoenzyme, included as control, was activated by cAMP with an EC<sub>50</sub> of 75 nM in agreement with <xref ref-type="bibr" rid="bib44">Herberg et al., 1996</xref>, but was completely insensitive to inosine. We conclude that the PKAs of <italic>T. cruzi</italic> and <italic>L. donovani</italic> are also cAMP-independent nucleoside activated kinases. The same order of potency was found among the three tested nucleosides, adenosine being the weakest activator (EC<sub>50</sub> ~6–8 µM) of PKA in the three parasite species (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b–c</xref>, <xref ref-type="table" rid="table1">Table 1</xref>).</p></sec><sec id="s2-3"><title>Binding of nucleosides to kinetoplastid PKAs</title><p>To further investigate purine nucleoside-specific allosteric regulation of kinetoplastid PKAs, nucleoside binding parameters were determined for the isolated R-subunits. The N-terminally truncated PKARs of the respective species containing the two tandem CNBs were expressed in <italic>E. coli</italic> and purified. Initially, binding assays with natively purified PKAR were inconclusive and highly variable using several methods. We concluded that the purified PKAR was at least partially bound by ligands or metabolites derived from <italic>E. coli</italic>, similar to the mammalian PKAR subunit that tightly binds cAMP when purified from bacteria (<xref ref-type="bibr" rid="bib18">Buechler et al., 1993</xref>). To confirm this directly, TbPKAR or HsPKARIα purified from <italic>E. coli</italic> were boiled to denature protein and were separated by centrifugation. Supernatants containing released ligands were collected and tested in kinase assays with purified holoenzyme as before (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). The supernatant of the boiled HsPKARIα fully activated the mammalian holoenzyme, but not the <italic>T. brucei</italic> holoenzyme, as would be expected for cAMP. In contrast, the supernatant from boiled TbPKAR fully activated the <italic>T. brucei</italic> holoenzyme but not the mammalian one (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b</xref>). In the HsPKARIα-derived supernatant only cAMP was detected by LC-MS (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2d</xref>), whereas in the TbPKAR-derived supernatant nucleosides (predominantly inosine) were detected (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2c</xref>). This experiment qualitatively showed tight binding of nucleosides to TbPKAR in <italic>E. coli</italic>. Subsequently, we routinely denatured the purified His-tagged regulatory subunits to remove any pre-bound ligands (see Materials and methods). Refolding conditions were optimized by a buffer screen and monitored by differential scanning fluorimetry (nanoDSF; <xref ref-type="bibr" rid="bib76">Niesen et al., 2007</xref>) and size exclusion chromatography (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a–d</xref>). The thermal stability of proteins was determined by nanoDSF that records changes of the ratio of intrinsic fluorescence at two wavelengths (330 and 350 nM). Natively purified TbPKAR(199-499) unfolded at T<sub>m</sub> of 59,5 °C. When refolded in absence of ligand (APO form) the T<sub>m</sub> was only 42,3 °C (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>). This is interpreted as stabilization of the purified TbPKAR by its partial loading with nucleosides from <italic>E. coli</italic>. Indeed, upon saturating the ligand-bound state of the refolded and the natively purified protein preparations by addition of excess inosine, the T<sub>m</sub> raised to 68 °C for both. The identical T<sub>m</sub> strongly indicates correct folding after renaturation. Ligand-depleted LdPKAR1(200–502) was prepared in the same way (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c–d</xref>), whereas for TcPKAR the yield of refolded protein (≤2 µM) was too low to carry out further experiments. Isothermal titration calorimetry (ITC) measurements showed high affinity binding of inosine and guanosine to both TbPKAR (<xref ref-type="fig" rid="fig1">Figure 1d</xref>) and LdPKAR1 (<xref ref-type="fig" rid="fig1">Figure 1e</xref>) with nanomolar K<sub>D</sub> values, matching closely the EC<sub>50</sub> values for kinase activation (<xref ref-type="table" rid="table1">Table 1</xref>). The close match of binding K<sub>D</sub> and activation EC<sub>50</sub> values for inosine and guanosine suggests that the K<sub>D</sub> measured for PKAR expressed in <italic>E. coli</italic> is an excellent proxy for the binding K<sub>D</sub> to the holoenzyme. Adenosine, the weakest activator, is also the weakest binder. Inosine did not bind at all to human PKARIα, which bound cAMP with a K<sub>D</sub> of 23 nM (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1d</xref>). LdPKAR1 did not bind to cAMP (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1d</xref>) as shown before for TbPKAR (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>). The binding data thus support nucleoside-specificity and cAMP independence of the trypanosomatid PKAs. The stoichiometry of purine nucleoside binding to TbPKAR as calculated from ITC data was N ≈1, apparently lower than expected for the two binding sites occupied by inosine in the co-crystal structures (see below). We cannot exclude the possibility that a fraction of the refolded protein unfolds or aggregates after purification or is bound to remaining traces of the ligand and therefore not available for binding at the time of ITC analysis (see Materials and methods). The thermodynamic signature of nucleosides binding to kinetoplastid PKA resembles that of mammalian PKA bound by cAMP (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). The enthalpic contribution to binding (∆H), indicating strong hydrogen bonding, is counteracted by a relatively large loss of entropy (T∆S), indicating bound-state conformational constrains.</p></sec><sec id="s2-4"><title>Structure of the nucleoside-binding pockets</title><p>To evaluate the binding mode, we solved the crystal structures of <italic>T. cruzi</italic> PKAR(200-503) and <italic>T. brucei</italic> PKAR(199-499) bound to inosine at 1.4 Å and 2.1 Å resolution, respectively (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1e, f</xref>, ). Attempts to crystallize LdPKAR1(200–502) were unsuccessful. The structures of TbPKAR and TcPKAR show high overall similarity. Calculated RMSD of Cα alignment was 0.796 Å for the entire proteins and 0.281/0.342 Å for CNB-A and CNB-B, respectively. Residues that contribute to high affinity binding by interacting with the ribose moiety of inosine are identical in both structures (<xref ref-type="fig" rid="fig2">Figure 2a and b</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1g</xref>; <xref ref-type="video" rid="video1">Video 1</xref>) and reside in a segment that we denoted ribose binding cassette (RBC), in analogy to the phosphate binding cassette (PBC) nomenclature for mammalian PKA (<xref ref-type="bibr" rid="bib23">Canaves and Taylor, 2002</xref>). These residues in site A (308-320<sup>TbPKAR</sup>, 309-321<sup>TcPKAR</sup>) and site B (432-445<sup>TbPKAR</sup>, 433-446<sup>TcPKAR</sup>) engage in the same interactions with inosine as in our previously described co-crystal structure of TcPKAR(200-503) with 7-CN-7-C-Ino (PDB: 6FTF) (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>). Likewise, the ‘capping’ by π-stacking with the purine ring in both sites (Y371/483<sup>TcPKAR</sup>, Y370/482<sup>TbPKAR</sup>) and the interacting residues in the lid-like αD helix are conserved. Thus, the binding mode of inosine and 7-CN-7C-Ino is almost identical. Minor differences are compatible with similar affinities of inosine and 7-CN-7-C-Ino. In site A, amino acid K294 donates a hydrogen bond to the cyano group of 7-CN-7-C-Ino (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). When bound to inosine, however, a different side chain rotamer of K294 is preferred, and a hydrogen bond can now be formed with the keto group in position 6 of the purine ring (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). In site B, the bulkiness of the cyano group displaces the side chain of Y485 by 1.5 Å, creating a small hydrophobic pocket able to fit C7-derivatives (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>; <xref ref-type="fig" rid="fig2">Figure 2c</xref>). Comparison of mammalian cAMP-bound PKARIα (PDB:1RGS) with nucleoside-bound kinetoplastid structures (PDB: 6FLO) clearly suggests that residues A202/R209<sup>PKARIα</sup> in site A and A326/R333<sup>PKARIα</sup> in site B are key to explain the altered ligand specificity of the kinetoplastid PKAR subunits (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). The arginine residues 209/333<sup>PKARIα</sup> conserved in most PKARs are replaced by polar amino acids, and the alanine residues 202/326<sup>PKARIα</sup> are replaced by glutamates highly conserved in the kinetoplastid PKARs. The arginine in PKARIα neutralizes the negative charge of the phosphate in cAMP and also donates hydrogen bonds to the exocyclic oxygens of the cyclic phosphate. The glutamates in kinetoplastid RBCs interacts with the 3’ and 5’ OH groups of ribose. Moreover, the arginines 209/333<sup>PKARIα</sup> and the glutamates 311/435<sup>TbPKAR</sup> occupy the same spatial position in the structures (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). A superposition of the mammalian and <italic>T. brucei</italic> structures shows a clash between the phosphate group of cAMP and the negatively charged side chain of E311/435<sup>TbPKAR</sup> (<xref ref-type="fig" rid="fig2">Figure 2d</xref> insets). The high-resolution crystal structures of <italic>T. brucei</italic> PKAR and <italic>T. cruzi</italic> PKAR thus provides a molecular rationale for absence of binding and activation by cAMP.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Crystal structures of <italic>T</italic>. <italic>cruzi</italic> and <italic>T. brucei</italic> PKAR bound to inosine.</title><p>(<bold>a</bold>) Electron density (ED) maps of site A (left) and site B (right) of <italic>T. cruzi</italic> PKAR(200-503) and corresponding ball and stick models of the hydrogen bond network around the bound inosine molecule. The inosine molecule was modeled into the omit map (Fo-Fc, 3σ, green) in each binding site. The surrounding protein atoms are shown together with a 2Fo-Fc map (1σ, dark blue). The black dashed lines represent hydrogen bonds (≤3 Å cutoff). Residues G309; E310; E312 and A321 belong to Ribose Binding Cassette A (RBC-A), while G433; E434 and E436 are part of Ribose Binding Cassette B (RBC-B). Capping residues (Y371 and Y483) taking part in a π-stacking interaction with the hypoxanthine ring of inosine are marked with an asterisk. Purine ring nomenclature is shown in the middle. PDB: 6HYI. (<bold>b</bold>) <italic>T. brucei</italic> PKAR(199-499) displayed as in A, Residues G308, E309, E311, and A320 are part of RBC-A while G432, E433, and E435 belong to RBC-B. Capping residues (Y370 and Y482) are marked with an asterisk. PDB: 6FLO. (<bold>c</bold>) Structural alignment of inosine-bound <italic>T. cruzi</italic> PKAR (PDB: 6HYI; protein grey, inosine yellow) and 7-CN-7C-Ino-bound <italic>T. cruzi</italic> PKAR (PDB: 6FTF; protein and ligand in purple). The different ligand binding to K294 (A-site, left) and a 1.5 Å displacement of Y485 due to the bulky cyano group of 7-CN-7-C-Ino (B-site, right) are shown at two magnifications. (<bold>d</bold>) Structural alignment of TbPKAR (PDB: 6FLO; protein grey, inosine yellow) and <italic>B. taurus</italic> PKARIα (PDB: 1RGS; protein magenta, cAMP cyan) for binding sites A (left) and B (right). In the blow-up panels, ligand-protein interactions are highlighted for the mammalian PKARIα (upper panel), TbPKAR (middle panel), and TbPKAR overlayed with the cAMP ligand of the aligned PKARIα structure. A clash between the exocyclic oxygens of cAMP and the side chain of glutamate residues (faded sphere-representation) is seen in both binding sites.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Protein purification and quality controls for ITC and crystallization experiments for TbPKAR, LdPKAR1, and TcPKAR.</title><p>(<bold>a, c</bold>) Size Exclusion Chromatogram (SEC) of refolded APO TbPKAR(199-499) and LdPKAR1(200–502), respectively, used for ITC. Purity and expected molecular mass of protein samples are confirmed by SDS-PAGE (inset). (<bold>b</bold>) Thermal denaturation profiles (nanoDSF) of refolded APO (RfAPO) and native (N) <italic>T. brucei</italic> PKAR(199-499) with and without ligands. (<bold>d</bold>) Same as b for LdPKAR1(200–502) in absence or upon addition of 1 mM inosine. (<bold>e–f</bold>) Size exclusion chromatograms of purified TcPKAR(200-503) and TbPKAR(199- 499). Ligands added for co-crystallization are given next to the image of a representative crystal. (<bold>g</bold>) Sequence alignment of RBC-A/PBC-A(left) and RBC-B/PBC-B (right) motifs within CNB-A (left) and CNB-B (right) of PKAR from <italic>T. brucei (T.b.), T. cruzi (T.c.), L. donovani (L.d.), and B. taurus (B.t</italic>). Numbering refers to sequence of <italic>T. brucei</italic> (top, green) and <italic>B. taurus</italic> (bottom, red). Degree of sequence conservation is indicated in a color code from red (high conservation) to blue (low conservation).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original Coomassie stained gel showing refolded (APO) LdPKAR1(200–502).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91040-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original Coomassie stained gel showing refolded (APO) LdPKAR1(200–502) (labelled).</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91040-fig2-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig2-figsupp1-v1.tif"/></fig></fig-group><media mimetype="video" mime-subtype="mp4" xlink:href="elife-91040-video1.mp4" id="video1"><label>Video 1.</label><caption><title>Description: Alignment between TcPKAR (PDB: 6HYI, light blue) and TbPKAR (PDB:6FLO, chain B, light gray) displaying an RMSD of 0.909 Å calculated by PyMOL.</title><p>Inosine is displayed in green and magenta in TbPKAR and TcPKAR, respectively.</p></caption></media></sec><sec id="s2-5"><title>Synthetic conversion of TbPKAR to cyclic nucleotide specificity</title><p>To identify the structural determinants of ligand specificity, we introduced site-directed amino acid changes in TbPKAR to restore binding and activation by cyclic nucleotides. Three residues in each of the binding sites were mutated: E311A, T318R, V319A in RBC-A and E435A, N442R, V443A in RBC-B (mutant 1 in <xref ref-type="table" rid="table2">Table 2</xref>). In addition to the arginines and glutamates discussed above, a third position (V319/V443) that differs in kinetoplastid PKA compared to other eukaryotic PKAs (<xref ref-type="bibr" rid="bib72">Mohanty et al., 2015</xref>; <xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>) was changed to alanine. The consensus PBC sequence of cAMP-dependent PKAs (<xref ref-type="bibr" rid="bib23">Canaves and Taylor, 2002</xref>) was thereby restored. Mutant PKAR subunits were co-expressed with <italic>T. brucei</italic> catalytic subunits in <italic>L. tarentolae</italic>, and holoenzymes were tandem affinity purified. Kinase activation by nucleosides and cyclic nucleotides was measured (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Mutant 1 restored kinase activation by cIMP (EC<sub>50</sub> 340 nM) and reduced activation potency of inosine &gt;21,000-fold compared to WT. Thus, we confirmed that replacing these key residues was sufficient for conversion to cyclic nucleotide specificity. Activation by cAMP was also restored, but at lower activation potency (EC<sub>50</sub> 33 µM). This corresponds to lower activation potency of adenosine compared to inosine for wild type TbPKA. The same ranking is also seen for the very low potencies of IMP, GMP, and AMP (<xref ref-type="table" rid="table1 table2">Tables 1 and 2</xref>). To confirm the binding mode of cAMP to the converted binding site, mutant 6 of TbPKAR(199-499) carrying the triple replacements in site A was expressed in <italic>E. coli</italic> and co-crystallized with cAMP (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>). A molecule of cAMP was bound to site A and an inosine molecule (captured during expression in <italic>E. coli</italic>) to the unmodified site B (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Structural similarity of mutant 6 to wild type TbPKAR was very high (Cα RMSD = 0.430 Å). All hydrogen bonds to cAMP observed in the PKARIα structure (PDB: 1RGS, <xref ref-type="fig" rid="fig3">Figure 3b</xref>, right) were also present between cAMP and homologous residues in the A-site pocket of TbPKAR mutant 6 (<xref ref-type="fig" rid="fig3">Figure 3b</xref>, left and <xref ref-type="video" rid="video2">Video 2</xref>). The only remarkable difference is that cAMP binds in an <italic>anti</italic>-conformation in mutant 6 and in the <italic>syn</italic>-conformation in the mammalian PKAR. The E311A and V319A replacements created additional space inside the pocket to accommodate the bulky phosphate group of cAMP. An altered conformer of cysteine 278 and slight displacement of the loop between β–2 and β–3 in site-A allowed R318 to be accommodated so that it can interact with an exocyclic oxygen of cAMP (<xref ref-type="video" rid="video2">Video 2</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Conversion of TbPKAR to cyclic nucleotide specificity (<bold>a</bold>) Structure of ligand binding sites of TbPKAR(199-499) mutant 6 crystallized in presence of 1 mM cAMP (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a</xref>, PDB: 6H4G).</title><p>The scheme above the electron density map highlights binding of cAMP to site A and inosine to site B. Below, the electron densities show the protein atoms inside the 2Fo-Fc (1σ, dark blue) map and ligands inside the Fo-Fc omit map (3σ, green). (<bold>b</bold>) Structural comparison between the A pocket of TbPKAR(199-499) mutant 6 (left) and BtPKARIα (right, PDB: 1RGS). The point mutations in mutant 6 are colored in purple (E311A), green (T318R) and orange (V319A). The same color code was used for the corresponding amino acids in BtPKARIα. Hydrogen bonds (3 Å) are indicated as dashed lines. (<bold>c</bold>) Thermal denaturation profiles (nanoDSF) of refolded APO (upper panel) and native mutant 6 TbPKAR(199-499) (middle panel) in the absence and presence of 1 mM ligands as indicated. The lower panel is a superposition of the thermal denaturation profiles of the two protein preparations (native and refolded APO) both incubated with 1 mM cAMP plus 1 mM inosine. (<bold>d</bold>) Mutational analysis of TbPKAR nucleoside binding sites. Relative kinase activation potency by inosine (orange) and cIMP (blue) is displayed as log<sub>2</sub> of the EC<sub>50</sub>[Wildtype]/EC<sub>50</sub> [Mutant<sub>n</sub>] ratio on the x-axis. Since up to 5 mM cIMP did not activate the WT, this value was taken as minimal estimate of EC<sub>50</sub>[WT] for cIMP. This uncertainty propagating into the calculated ratio is indicated by a color gradient at the right end of the columns. All data are taken from <xref ref-type="table" rid="table2">Table 2</xref>. Missing columns are not determined (n. d). The sequences of RBC-A and RBC-B of mutants 1–5, with mutated amino acids highlighted in red, are shown on the left to the respective columns.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Activation of mutant TbPKA holoenzymes by different ligands.</title><p>Representative dose-response curves for activation of <italic>T. brucei</italic> PKA holoenzyme mutants 1–7 by purine nucleosides and cyclic nucleotides as in <xref ref-type="fig" rid="fig1">Figure 1a</xref>. The sequences of RBC-A and RBC-B of mutants 1–7 are placed above the graphs with mutated amino acids highlighted in red. Calculated EC<sub>50</sub> values are taken from <xref ref-type="table" rid="table2">Table 2</xref>.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>In vitro kinase activation assays of mutants 1–7 of <italic>T.</italic> <italic>brucei</italic> PKAR-PKAC1 holoenzyme by nucleosides and cyclic nucleotides.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Protein purification and quality controls for ITC and crystallization experiments for TbPKAR mutant 6–8.</title><p>(<bold>a</bold>) Size exclusion chromatograms of purified TbPKAR mutant 6. Ligand added for co-crystallization is given next to the image of a representative crystal. (<bold>b, c</bold>) Size Exclusion Chromatogram (SEC) of APO TbPKAR mutant 6 refolded without cAMP (<bold>b</bold>) and with 5 mM cAMP (<bold>c</bold>). Green arrows indicate protein monomers, red arrows indicate aggregated or misfolded protein. (<bold>d</bold>) Circular dichroism spectra (average of 20 scans) of TbPKAR mutant 6 native (dark blue) and refolded APO (green) preparations. (<bold>e</bold>) Same as b for TbPKAR mutant 7 refolded in presence of 1 mM cIMP. (<bold>f</bold>) Thermal denaturation profiles (nanoDSF) of native (<bold>N</bold>) TbPKAR mutant 7 in absence (light blue) and upon incubation with 1 mM cAMP (green) or 1 mM cIMP (dark blue). (<bold>g</bold>) Same as f for native TbPKAR mutant 7 (red) and refolded APO TbPKAR mutant 7(RfAPO, black) in presence of 1 mM cIMP and 1 mM inosine. (<bold>h</bold>) Same as b for TbPKAR mutant 8.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig3-figsupp2-v1.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Activation of mutant TbPKA holoenzymes by different ligands.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2"/><th align="left" valign="bottom" rowspan="2">TbPKA holoenzyme</th><th align="left" valign="bottom" colspan="5">EC<sub>50</sub> (95% Cl)</th></tr><tr><th align="left" valign="bottom">Inosine</th><th align="left" valign="bottom">cIMP</th><th align="left" valign="bottom">Adenosine</th><th align="left" valign="bottom">Guanosine</th><th align="left" valign="bottom">cAMP</th></tr></thead><tbody><tr><td align="left" valign="bottom">WT</td><td align="left" valign="bottom">RBC-A -GELELMYQTPTVA-<break/>RBC-B -GELEFLNNHANVA-</td><td align="left" valign="bottom">18 (13–22) nM<xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom">- <bold><sup><xref ref-type="table-fn" rid="table2fn3">‡</xref></sup></bold></td><td align="left" valign="bottom">5 (3-7) µM<xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom">0.14 (0.08–0.19) µM<xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom">- <sup><xref ref-type="table-fn" rid="table2fn3">‡</xref></sup></td></tr><tr><td align="left" valign="bottom">Mut <bold><sup><xref ref-type="table-fn" rid="table2fn5">¶</xref></sup></bold></td><td align="left" valign="bottom" colspan="6"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">RBC-A -GELALMYQTPRAA-<break/>RBC-B -GELAFLNNHARAA-</td><td align="left" valign="bottom">300 (160–600) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">0.34 (0.2–0.7) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">- <sup><xref ref-type="table-fn" rid="table2fn3">‡</xref></sup></td><td align="left" valign="bottom">370 (130–1000) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">33 (26–45) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">RBC-A -GELALMYQTPTVA-<break/>RBC-B -GELAFLNNHANVA-</td><td align="left" valign="bottom">28 (23–35) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">nd<bold><sup><xref ref-type="table-fn" rid="table2fn6">**</xref></sup></bold></td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">- <bold><sup><xref ref-type="table-fn" rid="table2fn4">§</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">3</td><td align="left" valign="bottom">RBC-A -GELELMYQTPVVA-<break/>RBC-B -GELEFLNNHAVVA-</td><td align="left" valign="bottom">28 (15–37) nM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">nd</td></tr><tr><td align="left" valign="bottom">4</td><td align="left" valign="bottom">RBC-A -GELELMYQTPRVA-<break/>RBC-B -GELEFLNNHARVA-</td><td align="left" valign="bottom">36 (29–44) nM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">24 (22–26) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">- <bold><sup><xref ref-type="table-fn" rid="table2fn4">§</xref></sup></bold></td></tr><tr><td align="left" valign="bottom">5</td><td align="left" valign="bottom">RBC-A -GELALMYQTPRVA-<break/>RBC-B -GELAFLNNHARVA-</td><td align="left" valign="bottom">18 (15–20) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">0.5 (0.3–0.6) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">nd</td><td align="left" valign="bottom">90 (71–115) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td></tr><tr><td align="left" valign="bottom">6</td><td align="left" valign="bottom">RBC-A -GELALMYQTPRAA-<break/>RBC-B -GELEFLNNHANVA-</td><td align="left" valign="bottom">0.2 (0.16–0.25) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">14 (10–25) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">- <sup><xref ref-type="table-fn" rid="table2fn3">‡</xref></sup></td><td align="left" valign="bottom">1.2 (0.6–2.6) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">25 (19–38) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td></tr><tr><td align="left" valign="bottom">7</td><td align="left" valign="bottom">RBC-A -GELELMYQTPTVA-<break/>RBC-B -GELAFLNNHARAA-</td><td align="left" valign="bottom">1.1 (0.9–1.4) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">7 (5-11) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">21 (13–30) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">23 (17–32) µM<xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="left" valign="bottom">- <bold><sup><xref ref-type="table-fn" rid="table2fn4">§</xref></sup></bold></td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>mean half activation constants (EC<sub>50</sub>) and 95% confidence interval (95% Cl) for ≥ 3 biological replicates.</p></fn><fn id="table2fn2"><label>†</label><p>mean half activation constants (EC<sub>50</sub>) and 95% confidence interval (95% Cl) for technical triplicate of a single biological experiments­­.</p></fn><fn id="table2fn3"><label>‡</label><p>no activation was detected up to a maximum concentration of 5 mM.</p></fn><fn id="table2fn4"><label>§</label><p>no activation was detected up to a maximum concentration of 2 mM.</p></fn><fn id="table2fn5"><label>¶</label><p>number given to the respective mutant; site-directed mutations indicated in red.</p></fn><fn id="table2fn6"><label>**</label><p>not determined.</p></fn></table-wrap-foot></table-wrap><media mimetype="video" mime-subtype="mp4" xlink:href="elife-91040-video2.mp4" id="video2"><label>Video 2.</label><caption><title>Description: Alignment between A-site of PKARIα (PDB: 1RGS, gray, aa: 152–225) and A-site from mutant 6 (PDB: 6H4G, light green, aa: 259–332).</title><p>In mammalian PKAR, cAMP binds in the <italic>syn</italic>-conformation, while in Mutant 6 it binds in the <italic>anti</italic>-conformation. Of particular note is Cys278 in TbPKAR mutant 6, which is significantly displaced to the newly inserted R318. Hydrogen bonds &lt;3 Å are shown as black dashes.</p></caption></media><p>Simultaneous binding of cAMP and inosine to mutant 6 was supported by nanoDSF analysis. The refolded protein (APO form) had a low T<sub>m</sub> measured by nanoDSF, but T<sub>m</sub> raised by 14 °C upon addition of cAMP and by 28 °C upon addition of both cAMP and inosine (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). cAMP also stabilized the refolded mutant 6 protein during purification (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2b</xref>, c). Correct refolding of this mutant was indicated by identical T<sub>m</sub> after addition of cAMP plus inosine to native and refolded protein preparations and was confirmed by circular dichroism spectroscopy (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2d</xref>). To evaluate the role of individual amino acids in the ‘conversion set’, single and double mutations were introduced at equivalent positions in RBC A and RBC B of TbPKAR and co-expressed with the <italic>T. brucei</italic> catalytic subunit PKAC1 in <italic>L. tarentolae</italic>. The tandem affinity purified holoenzymes were used for kinase assays to determine EC<sub>50</sub> values (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig3">Figure 3d</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Replacement of positions 318/442<sup>TbPKAR</sup> by arginines in both RBCs (mutant 4) was sufficient for response to cIMP (EC<sub>50</sub> 24 µM). To achieve cyclic nucleotide activation in the upper nM range the glutamates 311/435 needed to be replaced by alanines as well in mutant 5 (<xref ref-type="fig" rid="fig3">Figure 3d</xref>, <xref ref-type="table" rid="table2">Table 2</xref>). The potency of inosine was 1556-fold reduced by E311A/E435A<sup>TbPKAR</sup> (mutant 2) alone. In contrast, substituting the non-conserved amino acids at positions 318/442 by arginine (mutant 4) or a valine (mutant 3) did not have a significant effect on inosine response. The adjacent valine 319/443<sup>TbPKAR</sup> seems to contribute to activation by inosine 17-fold (compare mutants 1 and 5, <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3d</xref>). In the B site this valine engages in hydrophobic interactions with the side chains of Y485 and K488, both belonging to the kinetoplastid-specific αD helix that supports inosine binding by sealing the binding pocket (<xref ref-type="video" rid="video3">Video 3</xref>). The EC<sub>50</sub> values of all mutants tested were almost 100-fold higher for cAMP than for cIMP, not surprising as inosine is a much better activator of the WT protein compared to adenosine (<xref ref-type="table" rid="table1 table2">Tables 1 and 2</xref>).</p><media mimetype="video" mime-subtype="mp4" xlink:href="elife-91040-video3.mp4" id="video3"><label>Video 3.</label><caption><title>Description: Sphere representation of the B-site from TbPKAR (PDB:6FLO, chain B, aa: 378–490) showing residues Y484, Y485, and K488 in the αD helix in purple, V443 in green, inosine in blue and the rest of the protein in yellow.</title><p>V443 is sandwiched between the alpha-D helix and the beta barrel, taking part in hydrophobic contacts to both sides.</p></caption></media></sec><sec id="s2-6"><title>The αD helix is required for high affinity binding to the B-site</title><p>The binding and activation assays used so far average K<sub>D</sub> and EC<sub>50</sub> values over both the A-site and B-site of TbPKAR. As these sites are structurally not identical, we considered a kinetoplastid-specific feature of the B-site, the αD-helix (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>). This is a helical extension of αC beyond the small loop containing the capping residue Y482 at the end of αC that stacks with the purine ring of inosine (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). In the ligand-bound structures of TbPKAR and TcPKAR, this helix docks to theβ-barrel of the B-site, covers the binding pocket and shields the ligand from solvent (<xref ref-type="fig" rid="fig4">Figure 4a</xref>, <xref ref-type="video" rid="video4">Video 4</xref>). Only one water molecule was found inside the binding pocket (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). Two tyrosine residues (Y484, Y485) in αD are conserved in trypanosomatids, as are amino acids in the beta barrel of the B-site that are linked to these two amino acids via hydrogen bonds (<xref ref-type="fig" rid="fig4">Figure 4b and c</xref>). Y484 interacts with the backbone of V443 and R413 while Y485 forms two hydrogen bonds to the side chains of N438 and H440 (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). In silico structure relaxation (<xref ref-type="fig" rid="fig4">Figure 4d</xref>) under an OPLS3 force field (Maestro-Schrödinger) showed two histidines (H440, H430) engaging in salt bridge interactions with the ribose-binding glutamates (E433 and E435), together forming a stable structure on which the αD-helix can dock (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). The beta factor representation of TbPKAR suggests that proline 480 functions as a hinge between αC and αD, as the average displacement of P480 is higher than that of the other residues around it, likely correlating with higher mobility (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). The αD-helix might therefore function as a lid to close the pocket and determine ligand affinity. This hypothesis was confirmed by ITC measurements of inosine binding to the Y484A/Y485A double mutant (mutant 8). To selectively measure nucleoside binding to the mutated Y484A/Y485A B-site, the A-site was made unavailable for nucleoside binding by using TbPKAR mutant 6 as context and refolding of the protein in the presence of cAMP (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2h</xref>). Mutant 8 shows 82-fold decreased affinity for inosine (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). The αD is therefore important for high binding affinity of 6-oxopurine nucleosides to the B-site.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>The αD helix of TbPKAR determines high binding affinity and ligand selectivity of the B-site.</title><p>(<bold>a</bold>) C-terminal helices αB (grey), αC (purple) and αD (green) in CNB-B of TbPKAR, illustrating the lid-like position of the αD helix. The ribose binding cassette (RBC, residues 432–445) is shown in surface representation (grey). Inosine (yellow) and one water molecule (blue) are sandwiched between RBC-B and the αD helix (enlarged view in the blow-up panel). The 90<sup>o</sup> rotations of the structure show that the αC and αD helices are orthogonally positioned to each other. (<bold>b</bold>) The hydrogen-bond network formed between Y484 and Y485 in αD helix and amino acids in the beta barrel of site B. Hydrogen bonds (3 Å) are displayed as black dashed lines. (<bold>c</bold>) Sequence alignment of C-terminal domains from <italic>T. brucei</italic>, <italic>T. cruzi,</italic> and <italic>L. donovani</italic> PKARs. Only TbPKAR numbering is shown. Red arrows mark residues involved in the hydrogen bond network with Y484, black arrows mark residues involved in the hydrogen bond network with Y485. (<bold>d</bold>) Extended network of hydrogen bonds and salt bridges (purple dashed lines) between two conserved histidines (H430 and H440) and the ribose-binding glutamates E433 and E435. (<bold>e</bold>) Beta factor representation of TbPKAR site B showing a higher overall atom displacement in the crystal structure of the αD helix and in particular of P480. The Beta factor value increases from blue to red and from thin to thick, indicating an increase of atom displacement in the crystal. (<bold>f</bold>) Representative binding isotherm (ITC) for inosine binding to TbPKAR mutant 8 (mutant 6 with additional substitutions Y484A, Y485A). Data representation as in <xref ref-type="fig" rid="fig1">Figure 1d</xref>, the K<sub>D</sub> value is taken from . (<bold>g, h</bold>) Representative binding isotherms (ITC) for mutant 6 refolded in presence of 1 mM cAMP (<bold>g</bold>) and mutant 7 refolded in presence of 1 mM cIMP (<bold>h</bold>). Data representation as in <xref ref-type="fig" rid="fig1">Figure 1d</xref>, the K<sub>D</sub> values are taken from . For sequences of mutants see <xref ref-type="table" rid="table2">Table 2</xref>, for purity and non-aggregated state of R subunits see <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2c</xref>, e.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>ITC measurements for inosine titrated to <italic>T.</italic> <italic>brucei</italic> PKAR mutant 8.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>ITC measurements for inosine, guanosine, or adenosine titrated to <italic>T.</italic> <italic>brucei</italic> PKAR mutant 6.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig4-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>ITC measurements for inosine, guanosine, or adenosine titrated to <italic>T.</italic> <italic>brucei</italic> PKAR mutant 7.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Docking of nucleosides to A and B site of TbPKAR.</title><p>(<bold>a</bold>) Purine nucleosides (guanosine and adenosine) were docked into site A in the <italic>T. brucei</italic> PKAR crystal structure (PDB: 6FLO, chain B,) using GLIDE (<xref ref-type="bibr" rid="bib36">Friesner et al., 2004</xref>), as implemented in Maestro (Schrödinger). Best poses were chosen according to the Glide G score (GG), given in the figure. (<bold>b</bold>) Same as A for site B. As a control, re-docking of inosine (magenta) was performed for comparison with the ligand in the crystal structures (yellow). RMSD values are 0.035 Å for site A and 0.036 Å for site B.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig4-figsupp1-v1.tif"/></fig></fig-group><media mimetype="video" mime-subtype="mp4" xlink:href="elife-91040-video4.mp4" id="video4"><label>Video 4.</label><caption><title>Description: Surface representation of the B-site from TbPKAR (PDB:6FLO, chain B, aa: 378–490) showing an inosine molecule (blue spheres) locked inside the protein with no access to solvent.</title><p>The αD helix (N481 to end) is depicted in dark purple.</p></caption></media></sec><sec id="s2-7"><title>Site-selective binding and synergism of nucleosides</title><p>The specific role of the αD-helix in site B prompted us to investigate binding affinities and ligand specificity of both sites individually. As interdomain CNB-A to CNB-B contacts are important for the allosteric activation mechanism of mammalian PKAR (<xref ref-type="bibr" rid="bib2">Akimoto et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Berman et al., 2005</xref>; <xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>; <xref ref-type="bibr" rid="bib68">Malmstrom et al., 2015</xref>), we analysed the contribution of each site in the R-subunit context. Mutant 6 with site A converted to cyclic nucleotide specificity (E311A, T318R, V319A) was blocked by excess of cAMP during refolding and was used to measure nucleoside binding to the non-mutated site B (<xref ref-type="fig" rid="fig4">Figure 4g</xref>). The corresponding mutant 7 with site B converted to cyclic nucleotide specificity was refolded in presence of cIMP to block this site and allow measurements of nucleoside binding affinity to the non-mutated A-site (<xref ref-type="fig" rid="fig4">Figure 4h</xref>). Correct refolding of mutant 6 and 7 was monitored by size exclusion chromatography and comparison of native and refolded protein by nanoDSF (<xref ref-type="fig" rid="fig3">Figure 3c</xref>; <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Inosine bound to mutant 6 and 7, and to the wildtype protein with similar high affinity (K<sub>D</sub> 9–18 nM). Adenosine had two orders of magnitude lower affinity for site B than inosine (K<sub>D</sub>1.1 µM) but displayed high affinity for site A (K<sub>D</sub> 82 nM). In contrast, guanosine bound with highest affinity of all nucleosides to site B (K<sub>D</sub> 6 nM), but with 36-fold lower affinity to site A (K<sub>D</sub> 221 nM). The preference of mutant 7 for cIMP over cAMP also reflects the B-site specificity for 6-oxo purines. In silico docking of inosine, guanosine and adenosine to site A and B of TbPKAR (PDB: 6FLO, chain B) using GLIDE (<xref ref-type="bibr" rid="bib36">Friesner et al., 2004</xref>) provided an explanation for the much lower binding affinity of adenosine to the B-site. Differences in interaction of the respective purine bases with the αD helix (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) include the hydrogen bonds of guanosine and inosine via the keto group at the C6 position to the backbone nitrogen of Y485. Since adenosine has an amino group in place of the C6 keto group, this specific interaction cannot take place. On the other hand, the C2 amino group of adenosine interacts with the keto group of N481 but apparently this interaction is not equivalent. Docking also suggests that the αD helix connects to guanosine, inosine and adenosine via three, two and one hydrogen bonds, respectively (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) which is perfectly compatible with weaker binding of adenosine to the B-site (<xref ref-type="fig" rid="fig4">Figure 4g</xref>). In the more solvent exposed site A, smaller differences in binding affinity of the three nucleosides (<xref ref-type="fig" rid="fig4">Figure 4h</xref>) correspond to smaller differences in the Glide G scores (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). In summary, molecular docking is compatible with the ITC data showing 37-fold binding selectivity of guanosine over adenosine at the B-site and 13-fold binding selectivity of adenosine over guanosine at the A-site (<xref ref-type="fig" rid="fig4">Figure 4g and h</xref>). An important implication of the site-selective binding of adenosine and guanosine is their possible synergism in kinase activation. This hypothesis was directly tested in kinase assays by determining the dose-response for adenosine in the presence of guanosine concentrations far below its EC<sub>50</sub>. As seen in <xref ref-type="fig" rid="fig5">Figure 5a</xref>, the dose response curves were clearly left shifted (up to 20-fold) by guanosine addition. Thus, adenosine can activate TbPKA in the nanomolar range upon co-stimulation by very low concentrations of guanosine.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Binding site selectivity and synergism of nucleosides.</title><p>(<bold>a</bold>) Dose-response curves for kinase activation of TbPKA by adenosine in presence of 10 nM or 20 nM guanosine. Error bars are m ± SD of technical triplicates, the calculated EC<sub>50</sub> values are given next to the respective curve. Basal kinase activity in the absence of any ligand is indicated by a horizontal dashed line. A green square (placed outside the log scale) represents the control with guanosine (10 or 20 nM) only. (<bold>b</bold>) Ratio of kinase activation over binding affinity (EC<sub>50</sub>/K<sub>D</sub>) for different purine nucleosides and individual binding sites A and B. Unavailable binding sites in mutants 6 and 7 are indicated by red crosses. Data are taken from <xref ref-type="table" rid="table2">Table 2</xref> and .</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>In vitro kinase activation assays of <italic>T.</italic> <italic>brucei</italic> PKAR-PKAC1 holoenzyme by adenosine in presence of 10 nM or 20 nM guanosine.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-91040-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig5-v1.tif"/></fig></sec><sec id="s2-8"><title>Allosteric kinase activation</title><p>Comparing ligand binding data (K<sub>D</sub>, , <xref ref-type="fig" rid="fig1">Figure 1d</xref>) and kinase activation EC<sub>50</sub> (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig1">Figure 1b</xref>) of WT TbPKA we noticed that K<sub>D</sub> and EC<sub>50</sub> values matched very well for inosine and guanosine that bind with high affinity to the B-site, whereas a sixfold weaker activation compared to binding is seen for adenosine that preferentially binds to the A-site. This indicates that the B-site is the gate keeper and that our data are compatible with the model of allosteric regulation established for mammalian PKA (<xref ref-type="bibr" rid="bib84">Rehmann et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>), where a conformational change upon B-site binding gives access to the ligand at the A-site. We then calculated the EC<sub>50</sub>/K<sub>D</sub> ratio (<xref ref-type="fig" rid="fig5">Figure 5b</xref>) for mutants 6 and 7 with either the B-site or the A-site intact. Both mutants show a high (&gt;100) EC<sub>50</sub>/K<sub>D</sub> ratio for nucleosides. This indicates that both binding domains are required in a ligand-bound conformation for efficient allosteric kinase activation by release of the catalytic subunit. The extreme (&gt;4500) EC<sub>50</sub>/K<sub>D</sub> ratio for adenosine and mutant 6 corresponds to the low affinity of adenosine to the B-site and confirms the role of that site in initiating the conformation change. The EC<sub>50</sub>/K<sub>D</sub> value of only 11 for mutant 6 and inosine is interpreted as weak binding of inosine to the mutated A binding site that we cannot exclude as the site is not blocked by cAMP in the kinase assays. Together, analysis of single binding site mutants and different nucleoside ligands in the context of the full length PKA provides strong support for conservation of an allosteric activation mechanism triggered by cooperative binding in hierarchical order, initiated by B-site binding.</p></sec><sec id="s2-9"><title>Ligands of trypanosome PKA in vivo</title><p>The biochemical and structural characterization of purified TbPKAR did not address the relative importance of the natural purine nucleosides for kinase activation in vivo in trypanosomes. The initial focus on inosine was due to the abundance of this nucleoside in <italic>E. coli</italic> and preloaded recombinant protein. We then quantified the loading of tagged PKAR with ligands upon rapid pulldown from <italic>T. brucei</italic> lysates. We expected at least a fraction of PKAR to be loaded with ligands due to the dynamic equilibrium between dissociated, ligand-bound and C-subunit-bound (holoenzyme complex) state. Tagged TbPKAR, but not endogenous TbPKAR was efficiently pulled down via the tag. Indeed, C subunits were co-purified, indicating only partial holoenzyme dissociation (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Blood stream forms (BSF) and the procyclic fly vector stage of <italic>T. brucei</italic> (PCF) expressing tagged TbPKAR were used in these experiments and compared to matched isogenic wild type and <italic>∆pkar/∆pkar</italic> knock out controls. Nucleosides were released from PKAR bound to beads by boiling, then quantified by mass spectrometry using stable isotope labeled internal standards (<xref ref-type="fig" rid="fig6">Figure 6</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). In the procyclic stage (PCF), the relative amounts of nucleosides detected in the bead fraction were 63% adenosine, 30% guanosine, and 7% inosine (<xref ref-type="fig" rid="fig6">Figure 6a</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1a</xref>). In the bloodstream stage (BSF) 94% guanosine, 6% inosine and only background level of adenosine were found (<xref ref-type="fig" rid="fig6">Figure 6b</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1b</xref>). A priori the MS method did not exclude the additional presence of an unknown endogenous ligand of TbPKAR in trypanosomes. However, careful searches of the MS data sets for all known modified nucleosides detected in living systems from the MODOMICS database (<xref ref-type="bibr" rid="bib15">Boccaletto et al., 2018</xref>) did not return significant hits absent in the blank. Thus, we propose that the nucleosides guanosine, adenosine and possibly inosine are endogenous ligands and likely activators of trypanosomatid PKA, probably acting synergistically.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Quantification of ligands bound to TbPKAR in lysed cells HPLC-MS-based quantification of nucleoside amounts released from boiled His-tagged TbPKAR pulled down from lysed <italic>T</italic>. <italic>brucei</italic> (see <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</title><p>Inosine (red), guanosine (green), and adenosine (blue) were quantified using stable isotope-labeled internal standards. Error bars indicate SD from three biological replicates. Note the different Y-axis scales. Pie charts on the right show the relative amounts of nucleosides detected and quantified. (<bold>a</bold>) Procyclic stage <italic>T. brucei</italic> strain EATRO1125 expressing His-TbPKAR and parental control cells. Pulled down nucleosides from the control cell line were in the range of water blanks. (<bold>b</bold>) Bloodstream stage <italic>T. brucei</italic> MITat 1.2 single marker line expressing His-TbPKAR, parental control cells and isogenic <italic>Δtbpkar/Δtbpkar</italic> cells devoid of endogenous PKAR. The limit of quantification (LOQ), defined by the linear part of the standard curves for stable isotope-labeled nucleoside references, is given by a dashed line. Adenosine was below the LOQ.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>HPLC-MS quantification of ligands bound to TbPKAR in parasite lysates.</title><p>The left panels show western analysis of soluble fraction from lysed parasites expressing tagged TbPKAR or of control parasites (input), pulled down beads and supernatants (all in triplicate). Anti-PKAR, anti-PKAC1/2 and anti-His antibodies were used. Bound ligands were released by boiling of Ni-NTA beads in water and the aqueous fraction subjected to HPLC-MS analysis. Graphs on the right show chromatograms for the selected mass [M+H<sup>+</sup>]±0.003 m/z (given in parenthesis) for inosine, guanosine and adenosine (all red colored), and the matched stable isotope-labeled internal standards (all blue colored). Where peak quantification was in the linear range of the standard curves, m ± SD pmole of nucleoside per biological replicate of 8x10<sup>8</sup> or 2x10<sup>8</sup> cells is given for PCF or BSF, respectively (same values in <xref ref-type="fig" rid="fig6">Figure 6</xref>). For graphical reasons, the MS-signals were smoothened by Boxcar algorithm. (<bold>a</bold>) Procyclic stage (PCF) <italic>T. brucei</italic> strain EATRO1125 wild type cells and cells expressing His-TbPKAR, as indicated. Nucleoside amounts pulled down from wild type PCF were in the range of blanks. (<bold>b</bold>) Same as A for bloodstream stage <italic>T. brucei</italic> MITat 1.2 single marker <italic>Δtbpkar/Δtbpkar</italic> cells, wild type cells and cells expressing His-TbPKAR, as indicated. Only trace amounts of adenosine were detected.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-91040-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> with highlighted bands and sample labels.</title><p>BSF – blood stream stage, PCF – procyclic stage.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-91040-fig6-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91040-fig6-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>PKA was the first protein kinase studied at the structural and mechanistic level and became a paradigm for allosteric kinase regulation by ligands (<xref ref-type="bibr" rid="bib95">Taylor et al., 2012</xref>; <xref ref-type="bibr" rid="bib96">Taylor et al., 2021</xref>). It is highly conserved through evolution, including its activation by cAMP and present in most species, except plants. Here, we show that in the phylogenetically distant protozoan group <italic>Trypanosomatida</italic> nucleosides have replaced cyclic nucleotides as ligands of PKA. Inosine, guanosine and adenosine bind with high affinity to the regulatory subunit PKAR and efficiently activate PKA of <italic>T. brucei</italic>, <italic>T. cruzi,</italic> and <italic>Leishmania spp</italic>. Site-selective binding affinities and synergism of guanosine and adenosine suggest a new second messenger signaling pathway or nucleoside sensing mechanism in <italic>Trypanosomatida</italic>.</p><sec id="s3-1"><title>The CNB domain - a versatile ligand binding domain</title><p>In trypanosomatid PKAR orthologs, few residues in each CNB domain systematically deviate from the consensus of the cyclic nucleotide binding motif (<xref ref-type="bibr" rid="bib72">Mohanty et al., 2015</xref>; <xref ref-type="bibr" rid="bib23">Canaves and Taylor, 2002</xref>). By mutagenesis of these residues (E311, T318, V319 in RBC A and E435, N442, V443 in RBC B of TbPKA), we were able to restore binding and kinase activation by cyclic nucleotides and structurally interpret the determinants of altered ligand specificity. Whereas the crystal structures predict that the most critical glutamates E311<sup>RBC:A</sup> and E435<sup>RBC:B</sup> required for nucleoside binding preference would clash with the cyclic phosphate of cAMP (<xref ref-type="fig" rid="fig2">Figure 2d</xref>), kinase activation at high concentration suggests that this incompatibility is not absolute (mutant 4, <xref ref-type="fig" rid="fig3">Figure 3d</xref>), as expected for a dynamic structure in vivo. CNBs are present in most species and in a broad variety of proteins, reaching from protein kinases (<xref ref-type="bibr" rid="bib30">Diller et al., 2001</xref>; <xref ref-type="bibr" rid="bib94">Su et al., 1995</xref>) to ion channels (<xref ref-type="bibr" rid="bib108">Zagotta et al., 2003</xref>) and transcription factors, such as the catabolite activator protein (CAP) in bacteria (<xref ref-type="bibr" rid="bib54">Kannan et al., 2007</xref>; <xref ref-type="bibr" rid="bib82">Passner and Steitz, 1997</xref>). The ancient CNB fold has been described as core module for allosteric regulation by cyclic nucleotides (<xref ref-type="bibr" rid="bib12">Berman et al., 2005</xref>; <xref ref-type="bibr" rid="bib54">Kannan et al., 2007</xref>). Here, we propose that the CNB is a module for allosteric regulation by a broader spectrum of small ligands. This is reminiscent of other families of ligand binding proteins like the G-protein-coupled receptors or steroid hormone binding domains in transcription factors that have been initially characterized by a limited set of ligands. Diverse ligands have later been identified for the ‘orphan’ members of those families (<xref ref-type="bibr" rid="bib28">Davenport et al., 2013</xref>). Future investigations might identify additional CNB domain ligands also outside the <italic>Trypanosomatida</italic> group.</p><p>In contrast to residues important for ligand specificity, the π-stacking interaction by the so-called capping residues (<xref ref-type="bibr" rid="bib106">Wu et al., 2004</xref>; <xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>) with the purine ring of cAMP or nucleosides are well conserved between mammalian and trypanosomatids. Single mutations of the mammalian PKA capping residues W260 <sup>RIα:CNB-A</sup> or Y371<sup>RIα:CNB-B</sup> that interact with cAMP reduced activation potency by 4.6 and ninefold, respectively and influence the cooperativity of the two binding sites (<xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>). The importance of stacking interactions with Y371 in site A and Y482 in site B of TbPKAR explains why allopurinol riboside, a purine derivative very similar to inosine with reduced delocalized electron system, is 120-fold less potent than inosine (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The biochemical and structural evidence for a distinct ligand specificity of trypanosomatid PKA that is provided here, will resolve a very controversial issue: whereas difficulties to detect cAMP-dependent kinase activity in <italic>T. brucei</italic> and <italic>Leishmania</italic> were reported long ago (<xref ref-type="bibr" rid="bib104">Walter, 1978</xref>; <xref ref-type="bibr" rid="bib10">Banerjee and Sarkar, 2001</xref>), cAMP regulation of <italic>T. cruzi</italic> and <italic>Leishmania</italic> PKA activity and binding of cAMP to LdPKAR1 in the µM range have been proposed by others (<xref ref-type="bibr" rid="bib47">Huang et al., 2006</xref>; <xref ref-type="bibr" rid="bib13">Bhattacharya et al., 2012</xref>). Our data contradict the latter reports and possible technical reasons have been discussed previously (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>; <xref ref-type="bibr" rid="bib3">Bachmaier and Boshart, 2013</xref>).</p></sec><sec id="s3-2"><title>The tail makes the affinity difference</title><p>The very high affinity of nucleosides to the B-site was surprising as the ionic interaction of the cyclic phosphate deep in the pocket is important for strong binding of cAMP in mammalian PKA (<xref ref-type="bibr" rid="bib94">Su et al., 1995</xref>; <xref ref-type="bibr" rid="bib44">Herberg et al., 1996</xref>). The C-terminal extension (αD helix) is so far only found in trypanosomatid PKAR and contains the conserved sequence (K/N)YxYY. Our crystal structures show that this helix covers the B binding site in the ligand-bound state like a lid and shields the ligand from solvent (<xref ref-type="video" rid="video4">Video 4</xref>). Inside the binding pocket, the capping residue (Y482) π-stacks with the purine ring that may additionally engage in T-shape π-stacking interaction with Y484 and Y485 from the αD helix (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). C-terminal extensions are found in some PKAR subunits for example RIIß (PDB: 1CX4; <xref ref-type="bibr" rid="bib30">Diller et al., 2001</xref>) or <italic>Plasmodium falciparum</italic> PKAR (PDB: 5K8S; <xref ref-type="bibr" rid="bib64">Littler et al., 2016</xref>). These differ from the αD helix in that they just seem to prolong the αC helix. In contrast, the αD helix is separated from αC by a proline resulting in a kink that positions the αD helix on top of the binding pocket. The helix is attached to the binding pocket by several hydrogen bonds donated by the conserved tyrosines Y484 and Y485 (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). Consequently, the Y484A/Y485A mutation reduced the binding affinity for inosine to site B drastically. The αD helix lid mechanism may compensate for the weaker bonds of the ribose moiety of nucleosides deep in the pocket, whereas cAMP binding is stabilized by a strong ionic interaction with the phosphate in cAMP-dependent PKARs.</p></sec><sec id="s3-3"><title>Site selectivity and synergism of nucleosides</title><p>The binding data for trypanosomatid PKARs show a clear affinity ranking of the three purine nucleosides: K<sub>D</sub>(ino)&lt;K<sub>D</sub>(guano)&lt;K<sub>D</sub>(adeno). The preference of inosine and guanosine over adenosine is most striking for the B-site. The structures and molecular docking show that the αD-helix contributes to the high affinity of guanosine and inosine, as in contrast to the adenine base, the 6-oxopurines can form several hydrogen bonds to the αD-helix. This preference is also seen as a 97-fold difference in kinase activation between cIMP and cAMP in mutant 1 (<xref ref-type="table" rid="table2">Table 2</xref>). Initially, binding of nucleosides to TbPKAR and LdPKAR1 was measured with recombinant proteins containing the complete C-terminus with both CNB domains. This averages over the affinity of two binding sites. To determine single binding site affinities, previous work on mammalian PKA used individual expressed CNB domains (<xref ref-type="bibr" rid="bib73">Moll et al., 2007</xref>; <xref ref-type="bibr" rid="bib67">Lorenz et al., 2017b</xref>). Here, we blocked either the A (mutant 6) or B site (mutant 7) of TbPKAR by conversion to cyclic nucleotide specificity to measure binding to the other site in the context of the intact protein. This strategy reduces the risk of protein truncation artefacts, but we are aware of the limitation of measuring binding to a ‘primed’ protein (the other binding site is occupied). The true affinity to the B-site in the holoenzyme (APO) state available in vivo cannot be easily determined. This in mind, a strong site preference of adenosine for site A and guanosine for site B was observed, whereas inosine bound equally to both sites. The αD-helix seems important for guanosine preference in site B (see above), but single amino acids contributing to adenosine preference in site A could not be identified by in-silico docking experiments (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). A co-crystal structure of TbPKAR with adenosine is not yet available. The site selective binding of adenosine and guanosine to sites A and B, respectively, of <italic>T. brucei</italic> PKAR is reminiscent of site selectivity of cyclic nucleotide analogues for mammalian PKAR. A synergistic effect on kinase activation of these synthetic compounds was exploited for development of potential anti-proliferative drugs (<xref ref-type="bibr" rid="bib90">Schwede et al., 2000</xref>; <xref ref-type="bibr" rid="bib25">Cho-Chung et al., 1989</xref>; <xref ref-type="bibr" rid="bib50">Huseby et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Gausdal et al., 2013</xref>). Priming mammalian RI and RII isoenzymes with B-site selective cyclic nucleotides led to an increase of activation potency of A-site selective compounds (<xref ref-type="bibr" rid="bib79">Ogreid et al., 1989</xref>; <xref ref-type="bibr" rid="bib31">Dostmann et al., 1990</xref>; <xref ref-type="bibr" rid="bib27">Corbin et al., 1986</xref>). We observed a comparable synergistic effect upon priming of TbPKA with 10–20 nM of the B-site selective guanosine, resulting in a 6–20-fold shift in activation potency by the A-site selective adenosine. In contrast to pharmacological synergism of drugs acting on mammalian PKA, the synergism of two endogenous ligands present in trypanosomes may have in vivo relevance by providing a logical AND switch to respond to and integrate over the two most important purine nucleosides in the cell.</p></sec><sec id="s3-4"><title>Allosteric regulation of PKA</title><p>A detailed model for the allosteric activation mechanism of mammalian PKA has been elaborated over many years (<xref ref-type="bibr" rid="bib94">Su et al., 1995</xref>; <xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>; <xref ref-type="bibr" rid="bib96">Taylor et al., 2021</xref>; <xref ref-type="bibr" rid="bib84">Rehmann et al., 2007</xref>). Is this activation mode also applicable to the nucleoside dependent PKA of trypanosomatids? The crystal structures of inosine bound TbPKAR and mammalian PKARIα (PDB: 1RGS) are highly homologous (rmds = 3.2 Å). Key sequence features implicated in the allosteric regulation, such as the salt bridge (E371, R475<italic><sup>TbPKAR</sup></italic>) keeping the B/C helix extended in the apo conformation, the capping residues (Y370 and Y482) that participate in ligand binding by π stacking (<xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>; <xref ref-type="bibr" rid="bib106">Wu et al., 2004</xref>) as well as residues involved in R-C interaction for example the inhibitory sequence (RRTTV, res. 201–206 in TbPKAR) (<xref ref-type="bibr" rid="bib56">Kim et al., 2005</xref>; <xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>) are conserved. The binding and kinase activation data for single site mutants of TbPKA (<xref ref-type="fig" rid="fig5">Figure 5b</xref>) clearly show that nucleoside binding to both sites is required for efficient kinase activation and suggests that the B-site has a ‘gatekeeper’ function that initiates the conformational change and leads to accessibility of the A-site, like in mammalian PKA. Subsequent ligand binding to the A-site then triggers dissociation of the catalytic subunit (<xref ref-type="bibr" rid="bib44">Herberg et al., 1996</xref>; <xref ref-type="bibr" rid="bib56">Kim et al., 2005</xref>; <xref ref-type="bibr" rid="bib57">Kim et al., 2007</xref>) and thereby releases the kinase from (auto)inhibition. The results of our single site mutant analysis of TbPKA (<xref ref-type="fig" rid="fig5">Figure 5b</xref>) are perfectly compatible with this model. Therefore, the basic allosteric mechanism seems to be conserved and may predate in evolution the separation of PKA into different CNB ligand specificities. More insight into the conformational detail of kinase activation by nucleosides will require the structure of a trypanosomatid PKA holoenzyme complex.</p></sec><sec id="s3-5"><title>Nucleosides as second messengers?</title><p>Inosine, guanosine, and adenosine were shown to bind to TbPKAR in vivo (<xref ref-type="fig" rid="fig6">Figure 6</xref>), whereas no compounds from an exhaustive list of nucleoside analogues previously identified in living organisms (MODOMICS database; <xref ref-type="bibr" rid="bib34">Dunin-Horkawicz et al., 2006</xref>; <xref ref-type="bibr" rid="bib16">Boccaletto et al., 2022</xref>; <xref ref-type="bibr" rid="bib15">Boccaletto et al., 2018</xref>) did match MS spectra from pulled down bound material. We may have missed a low affinity or labile ligand not captured by the pulldown procedure. However, in favour of a second messenger role of nucleosides, their binding affinities and activation potencies match well the affinity and potency of cAMP for mammalian PKA (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Furthermore, an unidentified second messenger would compete with the nucleosides in the cell and therefore require even higher affinity. Obviously, PKA might also serve as an intracellular nucleoside gauge. Trypanosomes are purine auxotroph and require sensitive regulation of purine uptake (<xref ref-type="bibr" rid="bib85">Rico-Jiménez et al., 2021</xref>). Reconciling a classical second messenger function of nucleosides with their role of metabolites in the cell seems less of a conceptual problem. First, an increasing number of metabolites with signaling function emerge (<xref ref-type="bibr" rid="bib9">Baker and Rutter, 2023</xref>) and second, subcellular compartmentalization of signal generation/degradation is well established for cAMP signaling and PKA that act mostly in microdomains (<xref ref-type="bibr" rid="bib19">Buxton and Brunton, 1983</xref>; <xref ref-type="bibr" rid="bib107">Zaccolo et al., 2021</xref>; <xref ref-type="bibr" rid="bib81">Paolocci and Zaccolo, 2023</xref>; <xref ref-type="bibr" rid="bib75">Musheshe et al., 2018</xref>). Compartmentalization of cAMP signaling also characterizes the trypanosome flagellum that serves as sensory organelle (<xref ref-type="bibr" rid="bib6">Bachmaier et al., 2022</xref>; <xref ref-type="bibr" rid="bib80">Ooi and Bastin, 2013</xref>; <xref ref-type="bibr" rid="bib77">Oberholzer et al., 2010</xref>; <xref ref-type="bibr" rid="bib93">Shaw et al., 2022</xref>). Microdomains enriched in nucleoside salvage pathway enzymes may facilitate kinase activation or signal termination by rapidly generating or degrading specific nucleosides. The compartmentalized nucleotide metabolism (<xref ref-type="bibr" rid="bib38">Ginger et al., 2008</xref>) in the flagellum exemplifies such a scenario. In fact, PKA of the trypanosomatid species analysed here is predominantly localized in the flagellum (<xref ref-type="bibr" rid="bib4">Bachmaier et al., 2016</xref>; <xref ref-type="bibr" rid="bib78">Oberholzer et al., 2011</xref>; <xref ref-type="bibr" rid="bib14">Billington et al., 2023</xref>), The subcellular distribution of nucleosides in trypanosomes is not known and even reliable values for total guanosine and inosine per cell are unavailable in the literature. Only adenosine was measured in the bloodstream stage of <italic>T. brucei</italic> in the range of 12–28 µM depending on the growth medium (<xref ref-type="bibr" rid="bib58">Kim et al., 2015</xref>). Taking the binding affinities into account, we can use the relative amounts of bound nucleosides pulled down with TbPKAR from cell lysates (<xref ref-type="fig" rid="fig6">Figure 6</xref>) as proxy for relative nucleoside concentrations in PKA containing compartments. Only a small fraction of PKAR bound inosine in vivo in both life cycle stages, indicating that this high affinity binder is not readily available for PKAR in the parasites. This is in contrast to <italic>E. coli</italic> where inosine seems more abundant (extrapolated from <xref ref-type="bibr" rid="bib11">Bennett et al., 2009</xref>) resulting in inosine bound to trypanosomatid PKAR when expressed in this heterologous system. In <italic>T. brucei</italic> bloodstream forms guanosine was captured but adenosine remained below the level of detection (<xref ref-type="fig" rid="fig6">Figure 6</xref>). In procyclic forms, guanosine and adenosine were both captured by PKAR, indicating a much higher adenosine/guanosine ratio in this life cycle stage. Based on these estimations, guanosine seems to be the primary physiological ligand in BSF, whereas adenosine and guanosine likely synergize to activate PKA in PCF (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Most PKAR pulled down from PCF would then have adenosine in the A-site and guanosine in the B-site. Termination of signaling may be supported by PKA subunit turnover since rapid degradation of the TbPKAC1 was seen upon depletion of TbPKAR by RNAi (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>).</p><p>As alternatives to a classical second messenger role of nucleosides, physiological activation of the PKA holoenzyme in vivo may be co-activated by nucleoside binding together with a second trigger like a posttranslational modification, redox state, specific protein-protein interaction or kinase regulation by liquid–liquid phase separation (<xref ref-type="bibr" rid="bib65">López-Palacios and Andersen, 2023</xref>; <xref ref-type="bibr" rid="bib40">Hardy et al., 2023</xref>). These triggers may allosterically shift the affinity or may be required for the final activating conformational change upon binding (<xref ref-type="bibr" rid="bib55">Khamina et al., 2022</xref>), giving nucleosides a more auxiliary role in the allosteric kinase regulation. In trypanosomatids abundant and regulated phosphorylation of PKA subunits has been reported (<xref ref-type="bibr" rid="bib99">Tsigankov et al., 2014</xref>; <xref ref-type="bibr" rid="bib101">Urbaniak et al., 2013</xref>). Kinase regulation may then even not require a signal-related change of the intracellular nucleoside concentration. The reasoning is inspired by the role of specific phosphorylations of mammalian PKA (<xref ref-type="bibr" rid="bib43">Haushalter et al., 2018</xref>) and the phenomenon of allosteric pluripotency described for the analogue Rp-cAMP, that acts as an inhibitor or activator depending on MgATP concentrations (<xref ref-type="bibr" rid="bib32">Dostmann and Taylor, 1991</xref>; <xref ref-type="bibr" rid="bib20">Byun et al., 2020a</xref>). Mechanistically, the opposite effects of Rp-cAMP are explained by formation of energetically stabilized mixed intermediate states of the kinase, in which CNB-A and CNB-B adopt different conformational states (<xref ref-type="bibr" rid="bib21">Byun et al., 2020b</xref>; <xref ref-type="bibr" rid="bib2">Akimoto et al., 2015</xref>). Similar intermediate states were also reported for <italic>Plasmodium falciparum</italic> PKG (<xref ref-type="bibr" rid="bib22">Byun et al., 2020c</xref>). Models for activation of the kinetoplastid PKA remain speculative as long as the upstream signaling that leads to PKA activation in vivo has not been elucidated in these organism. Future research will use kinase activation as readout for genome-wide screening to detect upstream pathway components regulating the nucleoside-dependent PKA.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>T. brucei</italic>)</td><td align="left" valign="bottom">TbPKAR</td><td align="left" valign="bottom">TriTrypDB</td><td align="left" valign="bottom">Tb927.11.4610</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>T. brucei</italic>)</td><td align="left" valign="bottom">TbPKAC1</td><td align="left" valign="bottom">TriTrypDB</td><td align="left" valign="bottom">Tb927.9.11100</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>T. cruzi</italic>)</td><td align="left" valign="bottom">TcPKAR1</td><td align="left" valign="bottom">TriTrypDB</td><td align="left" valign="bottom">TcCLB.506227.150</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>T. cruzi</italic>)</td><td align="left" valign="bottom">TcPKAC2</td><td align="left" valign="bottom">TriTrypDB</td><td align="left" valign="bottom">TcCLB.508461.280</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>L. donovani</italic>)</td><td align="left" valign="bottom">LdPKAR1</td><td align="left" valign="bottom">TriTrypDB</td><td align="left" valign="bottom">LdBPK_130160.1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Gene (<italic>L. donovani</italic>)</td><td align="left" valign="bottom">LdPKAC1</td><td align="left" valign="bottom">TriTrypDB</td><td align="left" valign="bottom">LINF_350045600</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">strain, strain background (<italic>E. coli</italic>)</td><td align="left" valign="bottom">Rosetta (DE3)</td><td align="left" valign="bottom">Novagen</td><td align="left" valign="bottom">SKU: 70954–3</td><td align="left" valign="bottom">Electrocompetent cells</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>L. tarentolae</italic>)</td><td align="left" valign="bottom">LEXSY T7-TR</td><td align="left" valign="bottom">Jena Bioscience</td><td align="left" valign="bottom">Cat.No.: LT-110</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>T. brucei</italic>)</td><td align="left" valign="bottom"><italic>T. brucei brucei</italic> stock Lister 427 clone MiTat 1.2</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1017/S0031182000046540">10.1017/S0031182000046540</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">All <italic>T. brucei brucei</italic> cell lines are derived in the laboratory from <italic>T. brucei brucei</italic> stock Lister 427 clone MiTat 1.2, originally obtained from G. Cross, NY</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>T. brucei</italic>)</td><td align="left" valign="bottom"><italic>T. brucei</italic><break/>EATRO 1125 AnTat1.1 90:13</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://doi.org/10.1101/gad.323404">10.1101/gad.323404</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (<italic>T. brucei</italic>)</td><td align="left" valign="bottom">MITat1.2SM 6HIS TbPKAR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">MITat1.2_SM blood stream forms (BSF) of <italic>T. brucei</italic> with expression of TbPKAR fused to a 6xHis tag</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>T. brucei</italic>)</td><td align="left" valign="bottom">EATRO11252T7 6HIS TbPKAR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">EATRO11252T7 procyclic forms (PCF) of <italic>T. brucei</italic> with expression of TbPKAR fused to a 6xHis tag</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>T. brucei</italic>)</td><td align="left" valign="bottom">MITat1.2SM PKAR-KO</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-09338-z">10.1038/s41467-019-09338-z</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">MITat1.2_SM BSF PKAR knock out</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>T. brucei</italic>)</td><td align="left" valign="bottom">pLEW100v5b1d-BSD_6His-Tev TbPKAR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Construct cloned and transfected into MITat1.2SM (BSF)</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>T. brucei</italic>)</td><td align="left" valign="bottom">pHD1146-puro_6xHis-Tev TbPKAR</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Construct cloned and transfected into EATRO11252T7 (PCF)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-PKAR (rabbit polyclonal)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-09338-z">10.1038/s41467-019-09338-z</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PKAC1/2 (rabbit polyclonal)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-09338-z">10.1038/s41467-019-09338-z</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">1:500-1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-6x His tag (mouse monoclonal)</td><td align="left" valign="bottom">Thermofisher scientific</td><td align="left" valign="bottom"/><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IRDye 800CW anti-mouse IgG (goat polyclonal)</td><td align="left" valign="bottom">LICOR</td><td align="left" valign="bottom">Cat# 925–32210</td><td align="left" valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IRDye 680LT anti-rabbit IgG (goat polyclonal)</td><td align="left" valign="bottom">LICOR</td><td align="left" valign="bottom">Cat# 925–69021</td><td align="left" valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 680 anti-rabbit IgG (goat Superclonal Recombinant)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat# A27042</td><td align="left" valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXSY_I-ble3 (vector)</td><td align="left" valign="bottom">Jena Bioscience</td><td align="left" valign="bottom">Cat# EGE-244</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXY_I-neo3 (vector)</td><td align="left" valign="bottom">Jena Bioscience</td><td align="left" valign="bottom">Cat# EGE-245</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXSY_I-ble3_TbPKAR (plasmid)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-09338-z">10.1038/s41467-019-09338-z</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Transfected in LEXSY expression system</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXSY_I-ble3_TbPKAR_mutant 1–7 (plasmids)</td><td align="left" valign="bottom">This Paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Transfected in LEXSY expression system; for specific mutation inserted see <xref ref-type="table" rid="table2">Table 2</xref></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXSY_I-ble3_TcPKAR1<break/>(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Transfected in LEXSY expression system</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXSY_I-ble3_LdPKAR1<break/>(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Transfected in LEXSY expression system</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXY_I-neo3_TbPKAC<break/>(plasmid)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-09338-z">10.1038/s41467-019-09338-z</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Transfected in LEXSY expression system</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXY_I-neo3_TcPKAC2<break/>(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Transfected in LEXSY expression system</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLEXY_I-neo3_LdPKAC1<break/>(plasmid)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Transfected in LEXSY expression system</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1 DNA-Novagen (vector)</td><td align="left" valign="bottom">Sigma-Aldrich Novagen</td><td align="left" valign="bottom">SKU 71146</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pET_SUMO Expression system</td><td align="left" valign="bottom">ThermoFisher Scientific</td><td align="left" valign="bottom">K30001</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1_TbPKAR(199-499)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-09338-z">10.1038/s41467-019-09338-z</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Recombinant expression of TbPKAR(199-499) in <italic>E. coli</italic></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1_TbPKAR(199-499)_mutant 6</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Recombinant expression of TbPKAR(199-499) mutant 6 in <italic>E. coli</italic></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1_TbPKAR(199-499)_mutant 7</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Recombinant expression of TbPKAR(199-499) in <italic>E. coli</italic></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1_TbPKAR(199-499)_mutant 8</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Recombinant expression of TbPKAR(199-499) in <italic>E. coli</italic></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1_TcPKAR1(200–503)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-019-09338-z">10.1038/s41467-019-09338-z</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Recombinant expression of TcPKAR(200–5003) in <italic>E. coli</italic></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pETDuet-1_HsPKAR1α</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/8393867/">8393867</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Recombinant expression of HsPKAR1α in <italic>E. coli</italic></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pET-11_Sumo3_LdPKAR1(200–502)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Recombinant expression of LdPKAR1(200–502) in <italic>E. coli</italic></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">TEV Protease</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# 8112 S</td><td align="left" valign="bottom">Cleavage of HIS-Tag in recombinant protein</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Sumo Protease</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">SKUSAE0067-2500UN</td><td align="left" valign="bottom">Cleavage of SUMO Tag in recombinant protein</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Hi Yield Plasmid Mini DNA Isolationkit</td><td align="left" valign="bottom">Süd-Laborbedarf GmBH, Germany</td><td align="left" valign="bottom">Art-Nr.: 30 HYPD100</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Inosine</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# 200-390-4</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Guanosine</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat#<break/>204-227-8</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Adenosine</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# 93029</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cAMP</td><td align="left" valign="bottom">Biolog Life Science Institute</td><td align="left" valign="bottom">Cat#<break/>A 001 H</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cGMP</td><td align="left" valign="bottom">Biolog Life Science Institute</td><td align="left" valign="bottom">Cat# G 001</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cIMP</td><td align="left" valign="bottom">Biolog Life Science Institute</td><td align="left" valign="bottom">Cat#<break/>I 001</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AMP</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# 54612</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">GMP</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# 226-914-1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">IMP</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# 57510</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2'-deoxyadenosine</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# D7400-250MG</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">3'-deoxyadenosine</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# C3394</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">5'-deoxyadenosine</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">D1771</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nebularine</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-208087</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Allopurinol riboside</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-217610</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Xanthosine</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# X0750</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Uridin</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# U3750</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cytidin</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# C122106</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">13C5-labeled Inosin</td><td align="left" valign="bottom">Omicron Biochemicals Inc</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41596-018-0094-6">10.1038/s41596-018-0094-6</ext-link></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">13C5-labeled Guanosin</td><td align="left" valign="bottom">Omicron Biochemicals Inc</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41596-018-0094-6">10.1038/s41596-018-0094-6</ext-link></td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">13C5-labeled Adenosin</td><td align="left" valign="bottom">Omicron Biochemicals Inc</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41596-018-0094-6">10.1038/s41596-018-0094-6</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 7.0</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Statistical testing</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Phenix</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1107/S0907444909052925">10.1107/S0907444909052925</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Model refinement</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Coot</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1107/S0907444909052925">10.1107/S0907444909052925</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Manual model building of protein structure</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Glide (Maestro)</td><td align="left" valign="bottom">Schroedinger LLC, New York, NY, 2023</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Molecular docking</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">The PyMOL Molecular Graphics System (Version 2.0)</td><td align="left" valign="bottom">Schrödinger, LLC</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Illustration of structural figures</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Preparation of PKA holoenzymes and kinase assay</title><p><italic>T. brucei</italic> PKAR/PKAC1(TriTrypDB: Tb927.11.4610 and Tb927.9.11100); <italic>T. cruzi</italic> PKAR1/PKAC2 (TriTrypDB: TcCLB.506227.150 and TcCLB.508461.280), <italic>L. donovani</italic> PKAR1/PKAC1 (TritrypDB: LdBPK_130160.1 and LINF_350045600) isoform ORFs were amplified by PCR from their respective gDNA and fused to a 6xHis tag and a TEV cleavage site. PKACs were N-terminally fused to a strep tag. Mutations were introduced by PCR site directed mutagenesis via overlap extensions as described previously in <xref ref-type="bibr" rid="bib46">Ho et al., 1989</xref>. Primer sequences are available in . The fusion ORFs were cloned into third generation pLEXSY vectors: pLEXSY_I-ble3 for PKARs and pLEXSY_I-neo3 for PKACs (Jena Bioscience). Holoenzymes were reconstituted in vivo by co-expression in <italic>L. tarentolae</italic> T7-TR according to the Jena Bioscience manual. The holoenzyme complexes were isolated using a tandem affinity purification protocol: Ni-NTA followed by Streptactin matrix. <italic>L. tarentolae</italic> cells were detergent lysed by vortex homogenization in Ni-NTA binding buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl, 20 mM imidazole, 0.5% Triton-X 100, Complete Mini EDTA-free protease inhibitor cocktail (Roche)). The soluble fraction was loaded onto a gravity flow Ni-NTA column. After washing with Ni-NTA wash buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl, 40 mM imidazole) the protein complex was eluted in Ni-NTA elution buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl, 250 mM imidazole). The eluate was immediately loaded onto the gravity flow Streptactin column, washed with Streptactin wash buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl) and eluted with Streptactin elution buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl, 2.5 mM desthiobiotin). All purification steps were carried out at 4 °C. The mammalian PKA holoenzyme: human RIα/mouse Cα was co-expressed and co-purified from <italic>E. coli</italic> strain APE304 as previously described in <xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>. The kinase assays with radiolabelled [γ32P] ATP were set up and performed as described in <xref ref-type="bibr" rid="bib42">Hastie et al., 2006</xref>. Briefly, a 50 µl kinase reaction mix was prepared at 4 °C by the addition of 5 µl of 10 x reaction buffer (500 mM MOPS pH 7; 1 M NaCl; 10 mM EGTA; 10 mM DTT; 1 mg/ml BSA; 100 mM MgCl<sub>2</sub>), 5 µl kemptide (1 mM), 5 µl purified PKA holoenzyme. A test run using known activating ligands (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>) was carried out and the kinase would then be diluted in 1 x reaction buffer, in order to work within the linear range of the assay. The Ligands were diluted in 30 µl H<sub>2</sub>O prior to addition. After temperature equilibration to 30 °C, the kinase reaction was started by addition of 5 µl 1 mM ATP spiked with [γ 32 P] ATP to give 200–400 cpm/pmole. The reaction was stopped after 10 min by pipetting 40 µl onto a 2x2 cm p81-phosphocellulose paper and immediate immersion into 75 mM phosphoric acid. Measurements were carried out in triplicates. Dose response curve fitting was performed with Graphpad prism’s non-linear regression for calculation of half activation constants EC<sub>50</sub> and 95% confidence interval.</p></sec><sec id="s4-2"><title>Protein expression and purification for ligand binding studies</title><p>N-terminally truncated <italic>T. brucei</italic> PKAR(199-499) and <italic>T. cruzi</italic> PKAR(200-503) were cloned into pETDuet1 (Novagen) with a N-terminal 6xHis-tag. TbPKAR(199-499) mutants 6 and 7 (for sequences see <xref ref-type="table" rid="table2">Table 2</xref>) were generated by site-directed mutagenesis and cloned into pETDuet1. N-terminally truncated <italic>L. donovani</italic> PKAR(200-502) was fused to a Sumo_Ubiquitin Tag in a pET_Sumo vector (ThermoFisher). Refolded (RfAPO) and native (N) protein samples were subjected to nano differential scanning fluorimetry (nanoDSF), whereas for isothermal titration calorimetry (ITC), only refolded protein was used. Native and refolded proteins were prepared as reported by <xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref> with the following modifications: native protein (N) eluted from affinity chromatography (Ni-NTA column) was dialyzed overnight and then directly probed for thermal stability using nanoDSF. Purification of LdPKAR1(200–502) by Ni-NTA affinity chromatography was followed by SenP2 protease mediated cleavage of the N-terminal Sumo tag during dialysis of the protein in 50 mM Hepes pH 7.5 and 50 mM NaCl (buffer B). After denaturation of TbPKAR(199-499) mutants 6 and 7, refolding occurred in a dialysis bag in presence of 1 mM cAMP or 1 mM cIMP, respectively. To mutant 7, additionally 6.5 moles of cIMP per mole of refolded protein were added before ITC measurements. Final elution of all proteins after Size Exclusion Chromatography (SEC) was in either 50 mM HEPES pH 7.5, 50 mM NaCl, and 1% DMSO (buffer A) or 50 mM HEPES pH 7.5 and 50 mM NaCl (buffer B). Preparation of cAMP-free human PKARIα was performed according to <xref ref-type="bibr" rid="bib18">Buechler et al., 1993</xref>.</p></sec><sec id="s4-3"><title>Isothermal titration calorimetry (ITC)</title><p>ITC measurements were carried out on a MicroCal PEAQ-ITC (Malvern) instrument. Refolded proteins were diluted to 10–20 µM in buffer A or B. A total of 100–200 µM ligand were diluted in the same buffer as the protein and DMSO concentration of protein and ligand samples was adjusted as accurately as possible. As we observed that the molar ratio N decreased with time after final purification, we did all ITC experiments within a day to avoid precipitation of the protein. 2–4 µl of ligand were injected in a series of 13–19 injections into the protein sample at 298 K. The Differential Power (DP) between reference and sample cell was maintained at 8–10 µcal s<sup>–1</sup> in all experiments. Data analysis was performed with the MicroCal PEAQ-ITC software applying a model with one binding site.</p></sec><sec id="s4-4"><title>Thermal shift analysis using Nano Differentiation Scanning Fluorimetry (nanoDSF)</title><p>For nano differential scanning fluorimetry (nanoDSF), a Prometheus NT.48 (Nanotemper Technologies, Munich) equipped with high sensitivity glass capillaries (PR-C006, Nanotemper) was used. The technique allows label-free monitoring of protein melting temperatures (Tm). Upon heating 10 μl of protein sample per capillary from 15<sup>o</sup> to 90<sup>o</sup>, at a rate of 1–2°C per minute, intrinsic fluorescence at 330 and 350 nm (F<sub>330</sub>/F<sub>350</sub>) was recorded and the ratio of both or only the fluorescence at 330 nm was plotted as function of temperature. The melting temperature (T<sub>m</sub>) was calculated from the first derivative of the curve, using the instrument’s built-in software. Native (N) and refolded (RfAPO) protein preparations of TbPKAR(199-499), TbPKAR(199-499) mutant 6 and 7, and LdPKAR1(200–502) were subjected to nanoDSF before and after incubation in 1 mM of ligand(s). Accurate protein refolding was assumed when the melting temperature (T<sub>m</sub>) of refolded and native samples, both loaded with an excess of 1 mM ligand, presented close matching values.</p></sec><sec id="s4-5"><title>Circular dichroism spectroscopy</title><p>For circular dichroism (CD) spectroscopy, native and refolded TbPKAR(199-499) samples from mutant 6 were prepared as described above with the following modifications: Refolding occurred in presence of 1 mM inosine and 1 mM cAMP, followed by a SEC on a Superdex 200 Increase 10/20 GL column (GE Healthcare) and elution in CD buffer (20 mM NaPi), free of chlorine. To ensure complete buffer change, the refolded protein was subsequently passed over a PD10 column (Ge Healthcare) and again eluted in CD buffer. Similarly, native protein was passed twice over PD10 columns with elution in CD buffer. Proteins were diluted to 2 µM (0.1mAU absorbance) and incubated with 10 µM inosine and 10 µM cAMP before measurement. The CD spectra were recorded using a Jasco J-815–150 S spectropolarimeter (Jasco, Tokyo, Japan) connected to a PTC 343 peltier set up to maintain the system at a constant temperature of 20 °C. The protein (sample volume = in 200 µL) was inserted into a rectangular quartz cell of 0.1 cm path length and the UV spectra recorded by averaging 20 scans in the wavelength of 185–260 nm. The CD signal was recorded in a window of –7–10 mdeg. The identification of the peaks in the spectra related to α-helices (193 nm) and ß-sheet (208 and 222 nm) enrichment were performed according to <xref ref-type="bibr" rid="bib39">Greenfield and Fasman, 1969</xref>.</p></sec><sec id="s4-6"><title>Crystallization, X-ray diffraction data collection and structure determination of ligand-bound PKARs</title><p>Protein purification for crystallization of TbPKAR(199-499), TbPKAR(199-499) mutant 6 and TcPKAR(200-503) was performed as described in <xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref> with the following modifications: Native protein eluted from a Ni-NTA column was cleaved by TEV protease for removal of the N-terminal 6xHis tag and then subjected to SEC. Protein freshly eluted from the Superdex 200 10/300 GL column was concentrated to at least 10 mg ml<sup>–1</sup> and, in order to ensure homogeneous ligand binding, incubated with either 1 mM inosine (TbPKAR(199-499) and TcPKAR(200-503)) or 1 mM cAMP (TbPKAR(199-499) mutant 6). Crystals grew within 7–10 days using sitting drops (100–500 nL) crystalizing via the vapor diffusion method (<xref ref-type="bibr" rid="bib29">Davies and Segal, 1971</xref>). Crystals of TbPKAR(199-499) were obtained in 50 mM Tris pH 8.0, 4% MPD, 0.2 M ammonium sulfate, 32% PEG 3350 at 4 °C. Crystals of TcPKAR(200-503) were obtained in 20% PEG 3350, 0.2 M Magnesium acetate at 4 °C. Crystals of TbPKAR(199-499) mutant 6 were obtained in 50 mM Tris pH 8.0, 0.2 mM Magnesium Chloride, 30% PEG 3350 at 4 °C. Prior to flash cooling in liquid nitrogen, the crystals were briefly soaked in a mother liquor solution made of the reservoir buffer and 40% (v/v) of ethylene glycol. The X-ray diffraction data were collected at the Swiss Light Source beamline PXIII and on a Bruker D8 venture Metaljet system, at 100 K. The collected data were processed using XDS and scaled using XSCALE (<xref ref-type="bibr" rid="bib52">Kabsch, 2010</xref>; <xref ref-type="bibr" rid="bib53">Kabsch, 2012</xref>). The structure of TbPKAR(199-499) with inosine was solved using the Sulphur SAD (Single-wavelength Anomalous Diffraction) phasing method (<xref ref-type="bibr" rid="bib33">Doutch et al., 2012</xref>). All other structures were solved by Molecular Replacement (MR) (<xref ref-type="bibr" rid="bib71">McCoy, 2007</xref>) using the structure of TbPKAR +inosine as a search model in the software Phaser as implemented in PHENIX (<xref ref-type="bibr" rid="bib63">Liebschner et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>). All the MR solutions presented a TFZ score (Translation Function Z-score) &gt;8 indicating correct solutions. The molecular models of the proteins were built using the 2Fo-Fc electron density map while the ligands were built using the difference map. The final structure was achieved by iterative cycles of manual building in Coot (<xref ref-type="bibr" rid="bib35">Emsley et al., 2010</xref>) and refinement using PHENIX. Data collection and refinement statistics are summarized in .</p></sec><sec id="s4-7"><title>In silico docking of nucleosides to TbPKAR</title><p>In silico docking was performed using the software Glide (<xref ref-type="bibr" rid="bib36">Friesner et al., 2004</xref>) as implemented in Maestro (Schrödinger). Ligands were built manually and prepared using LigPrep (Schrödinger). Ionization states and tautomers were not considered during ligand preparation. Stereoisomers had their chirality determined from the 3D structure (maximum 32 per ligand). The docking mode chosen was SP (Standard Precision). Chain B of TbPKAR (PDB: 6FLO) was chosen as a template for docking, since it presented a better overall electron density. For docking of inosine and guanosine to the A-site of TbPKAR the grid constrains used were E311 and water 96 (Match at least = 2). For docking of adenosine, the K293 conformer was changed to reach a hydrogen bond with the N7 of the purine ring. The grid restrains used were E311, K293 (Match at least = 2). For docking to the B-site, the chosen grid constraints were A444(N), G432(N), E435 and water 273 (Match at least = 2) for all three nucleosides. Poses were analysed by visual inspection and ranked according to Glide G-score (GG), a mathematical prediction of Gibbs Free Energy.</p></sec><sec id="s4-8"><title>Mass spectrometry analysis of ligands bound to TbPKAR in vivo</title><p>The TbPKAR ORF was N-terminally fused to a 6xHis tag by PCR and cloned into the pLEW82 expression vector and transfected into MITat1.2SM (single marker) blood stream form (BSF) cells and EATRO11252T7 insect stage form (PCF) cells, both of which expressed T7 polymerase and tetracycline repressor. Cell culture was exactly as reported before for BSF (<xref ref-type="bibr" rid="bib5">Bachmaier et al., 2019</xref>) and PCF (<xref ref-type="bibr" rid="bib89">Schenk et al., 2021</xref>). Transfected MiTat1.2SM blood stream forms were kept under constant selection with 1 µg/ml G418 and 2.5 µg/ml Bleomycin. Transfected EATRO11252T7 PCF cells were cultured under constant selection with 10 µg/ml G418, 25 µg/ml hygromycin and 2.5 µg/ml bleomycin. Selected clones were induced with 1 µg/ml tetracycline for 24 hours. The cells were harvested by centrifugation (1400 × <italic>g</italic> for 10 min), washed once with PBS and then detergent lysed in Ni-NTA binding buffer. The soluble fraction was incubated with magnetic Ni-NTA beads for 1 hr, followed by quick single washes in Ni-NTA binding buffer, Ni-NTA wash buffer, Streptactin wash buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub> pH 7.4, 150 mM NaCl) and finally MS-Grade H<sub>2</sub>O. The beads were suspended in MS-grade water and boiled at 95 °C for 5 min. Beads and denatured protein precipitate were removed by centrifugation at 10,000 × <italic>g</italic> for 10 min. The supernatant was then transferred to a fresh tube and stored at –20 °C until analysis. For LC-ESI-MS, the samples were chromatographed by a Dionex Ultimate 3000 HPLC system with a flow of 0.15 ml/min over an Interchim Uptisphere 120 Å 3HDO C18 column (150x2 mm), while maintaining the column temperature at 30 °C. Elution was performed with buffer A (2 mM HCOONH<sub>4</sub> in H<sub>2</sub>O, pH 5.5) and buffer B (2 mM HCOONH<sub>4</sub> in H2O/MeCN 20/80, pH 5.5), with a linear gradient from 0% to 15% buffer B in 45 min. The elution was monitored at 260 nm (Dionex Ultimate 3000 Diode Array Detector). The chromatographic eluent was directly injected into the ion source of a Thermo Finnigan LTQ Orbitrap XL without prior splitting. Ions were scanned by use of a positive polarity mode over a full-scan range of m/z 80–500 with a resolution of 30000. Parameters of the mass spectrometer were tuned with a freshly mixed aqueous solution of inosine (5 μM). The synthetic <sup>13</sup>C<sub>5</sub>-labeled internal isotope standards with an isotope enrichment of &gt;99% were procured from Omicron Biochemicals Inc The quantification of nucleosides was carried out, as described in <xref ref-type="bibr" rid="bib98">Traube et al., 2019</xref>, with the following amounts of the corresponding isotope labelled internal standards: 256.8 fmol [<sup>13</sup>C<sub>5</sub>]-inosine, 152.8 fmol [<sup>13</sup>C<sub>5</sub>]-guanosine, 662.8 fmol [<sup>13</sup>C<sub>5</sub>]-adenosine.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>CEO/CSO of BIOLOG Life Science Institute GmbH &amp; Co. KG</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Validation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Supervision, Validation</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Binding parameters from ITC measurements.</title></caption><media xlink:href="elife-91040-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Data collection and refinement statistics for the crystal structures.</title></caption><media xlink:href="elife-91040-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Results of searching the mass spectrometry data set (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) for nucleosides matches in the MODOMICS (<ext-link ext-link-type="uri" xlink:href="https://iimcb.genesilico.pl/modomics/">https://iimcb.genesilico.pl/modomics/</ext-link>) RNA modifications database.</title><p>Red cross: peak/mass not detected. Red: peak Rf/mass: detected but not significant over background. Green mass: peak Rf/mass: detected but not confirmed.</p></caption><media xlink:href="elife-91040-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of primers used in this study.</title></caption><media xlink:href="elife-91040-supp4-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-91040-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The coordinates of the crystal structures of <italic>T. cruzi</italic> PKAR bound to inosine, <italic>T. brucei</italic> PKAR bound to inosine and <italic>T. brucei</italic> PKAR (mutant 6) bound to cAMP and inosine have been deposited in the Protein Data Bank under the accession codes 6HYI, 6FLO, 6H4G, respectively. Genome sequence and annotation information was obtained from TritrypDB (<ext-link ext-link-type="uri" xlink:href="http://www.tritrypdb.org">http://www.tritrypdb.org</ext-link>). Results from a search of the MODOMICS database (Boccaletto et al. 2022) to identify nucleoside analogues identified in living organisms is provided as <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.The source data underlying figures, tables, and figure supplements are provided as source data files.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Volpato Santos</surname><given-names>Y</given-names></name><name><surname>Lorentzen</surname><given-names>E</given-names></name><name><surname>Basquin</surname><given-names>J</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Regulatory subunit of a cAMP-independent protein kinase A from <italic>Trypanosoma brucei</italic> at 2.1 Angstrom resolution</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb6FLO/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Volpato Santos</surname><given-names>Y</given-names></name><name><surname>Lorentzen</surname><given-names>E</given-names></name><name><surname>Basquin</surname><given-names>J</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Regulatory subunit of a cAMP-independent protein kinase A from <italic>Trypanosoma cruzi</italic> at 1.4 A resolution in complex with inosine</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb6HYI/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Volpato Santos</surname><given-names>Y</given-names></name><name><surname>Lorentzen</surname><given-names>E</given-names></name><name><surname>Basquin</surname><given-names>J</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Regulatory subunit of a cAMP-independent protein kinase A from <italic>Trypanosoma brucei</italic>: E311A, T318R, V319A mutant bound to cAMP in the A site</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb6H4G/pdb</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Dostmann</surname><given-names>WRG</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Durick</surname><given-names>K</given-names></name><name><surname>Xuong</surname><given-names>N-H</given-names></name><name><surname>Ten Eyck</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Varughese</surname><given-names>KI</given-names></name></person-group><year iso-8601-date="1996">1996</year><data-title>REGULATORY SUBUNIT OF CAMP DEPENDENT PROTEIN KINASE</data-title><source>RCSB Protein Data Bank</source><pub-id pub-id-type="accession" xlink:href="https://www.rcsb.org/structure/1RGS">1RGS</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Thomas Carell, LMU Chemistry, for generous support of SB, MS instrument time and discussions, Ralph Heermann, LMU Microbiology, and Michaela Smolle, LMU BMC, for advice, and Andreas Anger, LMU Gene Center for structural homology modelling in the early phase of the project. Eleni Polatoglou launched YVS in the laboratory. Access to nanoDSF instruments and advice was generously provided by NanoTemper Technologies GmbH (Munich, Germany). We are grateful to Oliver Plettenburg for discussions and Ricardo Biondi, IBIOBA, Buenos Aires for critical reading of the manuscript. The work was supported by the Bundesministerium für Bildung und Forschung (BMBF) grant 16GW0281-3 to MB and FS. YVS was supported by a fellowship from the Brazilian Science Without Borders/CNPq program and by the Life Sciences Munich (LSM) graduate school.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>LW</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>R</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Zwart</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PHENIX: a comprehensive python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akimoto</surname><given-names>M</given-names></name><name><surname>McNicholl</surname><given-names>ET</given-names></name><name><surname>Ramkissoon</surname><given-names>A</given-names></name><name><surname>Moleschi</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Melacini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mapping the free energy landscape of PKA inhibition and activation: a double-conformational selection model for the tandem cAMP-binding domains of PKA RIα</article-title><source>PLOS Biology</source><volume>13</volume><elocation-id>e1002305</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1002305</pub-id><pub-id pub-id-type="pmid">26618408</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><chapter-title>Kinetoplastid AGC Kinases</chapter-title><person-group person-group-type="editor"><name><surname>Doerig,</surname><given-names>C</given-names></name><name><surname>Späth,</surname><given-names>G</given-names></name><name><surname>Wiese</surname><given-names>M</given-names></name></person-group><source>Protein Phosphorylation in Parasites</source><publisher-name>Willey</publisher-name><fpage>99</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1002/9783527675401.ch05</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Witztum</surname><given-names>R</given-names></name><name><surname>Tsigankov</surname><given-names>P</given-names></name><name><surname>Koren</surname><given-names>R</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name><name><surname>Zilberstein</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Protein kinase A signaling during bidirectional axenic differentiation in Leishmania</article-title><source>International Journal for Parasitology</source><volume>46</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ijpara.2015.09.003</pub-id><pub-id pub-id-type="pmid">26460237</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Volpato Santos</surname><given-names>Y</given-names></name><name><surname>Kramer</surname><given-names>S</given-names></name><name><surname>Githure</surname><given-names>GB</given-names></name><name><surname>Klöckner</surname><given-names>T</given-names></name><name><surname>Pepperl</surname><given-names>J</given-names></name><name><surname>Baums</surname><given-names>C</given-names></name><name><surname>Schenk</surname><given-names>R</given-names></name><name><surname>Schwede</surname><given-names>F</given-names></name><name><surname>Genieser</surname><given-names>HG</given-names></name><name><surname>Dupuy</surname><given-names>JW</given-names></name><name><surname>Forné</surname><given-names>I</given-names></name><name><surname>Imhof</surname><given-names>A</given-names></name><name><surname>Basquin</surname><given-names>J</given-names></name><name><surname>Lorentzen</surname><given-names>E</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nucleoside analogue activators of cyclic AMP-independent protein kinase A of Trypanosoma</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1421</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09338-z</pub-id><pub-id pub-id-type="pmid">30926779</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Giacomelli</surname><given-names>G</given-names></name><name><surname>Calvo-Alvarez</surname><given-names>E</given-names></name><name><surname>Vieira</surname><given-names>LR</given-names></name><name><surname>Van Den Abbeele</surname><given-names>J</given-names></name><name><surname>Aristodemou</surname><given-names>A</given-names></name><name><surname>Lorentzen</surname><given-names>E</given-names></name><name><surname>Gould</surname><given-names>MK</given-names></name><name><surname>Brennand</surname><given-names>A</given-names></name><name><surname>Dupuy</surname><given-names>J-W</given-names></name><name><surname>Forné</surname><given-names>I</given-names></name><name><surname>Imhof</surname><given-names>A</given-names></name><name><surname>Bramkamp</surname><given-names>M</given-names></name><name><surname>Salmon</surname><given-names>D</given-names></name><name><surname>Rotureau</surname><given-names>B</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A multi-adenylate cyclase regulator at the flagellar tip controls African trypanosome transmission</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5445</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33108-z</pub-id><pub-id pub-id-type="pmid">36114198</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Gould</surname><given-names>MK</given-names></name><name><surname>Polatoglou</surname><given-names>E</given-names></name><name><surname>Omelianczyk</surname><given-names>R</given-names></name><name><surname>Brennand</surname><given-names>AE</given-names></name><name><surname>Aloraini</surname><given-names>MA</given-names></name><name><surname>Munday</surname><given-names>JC</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name><name><surname>de Koning</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Novel kinetoplastid-specific cAMP binding proteins identified by RNAi screening for cAMP resistance in <italic>Trypanosoma brucei</italic></article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>13</volume><elocation-id>1204707</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1204707</pub-id><pub-id pub-id-type="pmid">37475965</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>N</given-names></name><name><surname>Catta-Preta</surname><given-names>CMC</given-names></name><name><surname>Neish</surname><given-names>R</given-names></name><name><surname>Sadlova</surname><given-names>J</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Alves-Ferreira</surname><given-names>EVC</given-names></name><name><surname>Geoghegan</surname><given-names>V</given-names></name><name><surname>Carnielli</surname><given-names>JBT</given-names></name><name><surname>Newling</surname><given-names>K</given-names></name><name><surname>Hughes</surname><given-names>C</given-names></name><name><surname>Vojtkova</surname><given-names>B</given-names></name><name><surname>Anand</surname><given-names>J</given-names></name><name><surname>Mihut</surname><given-names>A</given-names></name><name><surname>Walrad</surname><given-names>PB</given-names></name><name><surname>Wilson</surname><given-names>LG</given-names></name><name><surname>Pitchford</surname><given-names>JW</given-names></name><name><surname>Volf</surname><given-names>P</given-names></name><name><surname>Mottram</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1244</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-21360-8</pub-id><pub-id pub-id-type="pmid">33623024</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>SA</given-names></name><name><surname>Rutter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Metabolites as signalling molecules</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>24</volume><fpage>355</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00572-w</pub-id><pub-id pub-id-type="pmid">36635456</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>C</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The cAMP-binding proteins of Leishmania are not the regulatory subunits of cAMP-dependent protein kinase</article-title><source>Comparative Biochemistry and Physiology. Part B, Biochemistry &amp; Molecular Biology</source><volume>130</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/s1096-4959(01)00232-9</pub-id><pub-id pub-id-type="pmid">11544092</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Kimball</surname><given-names>EH</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Osterhout</surname><given-names>R</given-names></name><name><surname>Van Dien</surname><given-names>SJ</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Absolute metabolite concentrations and implied enzyme active site occupancy in <italic>Escherichia coli</italic></article-title><source>Nature Chemical Biology</source><volume>5</volume><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/nchembio.186</pub-id><pub-id pub-id-type="pmid">19561621</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>HM</given-names></name><name><surname>Ten Eyck</surname><given-names>LF</given-names></name><name><surname>Goodsell</surname><given-names>DS</given-names></name><name><surname>Haste</surname><given-names>NM</given-names></name><name><surname>Kornev</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The cAMP binding domain: an ancient signaling module</article-title><source>PNAS</source><volume>102</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1073/pnas.0408579102</pub-id><pub-id pub-id-type="pmid">15618393</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name><name><surname>Das</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of A protein kinase A regulatory subunit from Leishmania having importance in metacyclogenesis through induction of autophagy</article-title><source>Molecular Microbiology</source><volume>83</volume><fpage>548</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2011.07950.x</pub-id><pub-id pub-id-type="pmid">22168343</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billington</surname><given-names>K</given-names></name><name><surname>Halliday</surname><given-names>C</given-names></name><name><surname>Madden</surname><given-names>R</given-names></name><name><surname>Dyer</surname><given-names>P</given-names></name><name><surname>Barker</surname><given-names>AR</given-names></name><name><surname>Moreira-Leite</surname><given-names>FF</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Vaughan</surname><given-names>S</given-names></name><name><surname>Hertz-Fowler</surname><given-names>C</given-names></name><name><surname>Dean</surname><given-names>S</given-names></name><name><surname>Sunter</surname><given-names>JD</given-names></name><name><surname>Wheeler</surname><given-names>RJ</given-names></name><name><surname>Gull</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Genome-wide subcellular protein map for the flagellate parasite <italic>Trypanosoma brucei</italic></article-title><source>Nature Microbiology</source><volume>8</volume><fpage>533</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01295-6</pub-id><pub-id pub-id-type="pmid">36804636</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boccaletto</surname><given-names>P</given-names></name><name><surname>Machnicka</surname><given-names>MA</given-names></name><name><surname>Purta</surname><given-names>E</given-names></name><name><surname>Piatkowski</surname><given-names>P</given-names></name><name><surname>Baginski</surname><given-names>B</given-names></name><name><surname>Wirecki</surname><given-names>TK</given-names></name><name><surname>de Crécy-Lagard</surname><given-names>V</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name><name><surname>Limbach</surname><given-names>PA</given-names></name><name><surname>Kotter</surname><given-names>A</given-names></name><name><surname>Helm</surname><given-names>M</given-names></name><name><surname>Bujnicki</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MODOMICS: a database of RNA modification pathways. 2017 update</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D303</fpage><lpage>D307</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1030</pub-id><pub-id pub-id-type="pmid">29106616</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boccaletto</surname><given-names>P</given-names></name><name><surname>Stefaniak</surname><given-names>F</given-names></name><name><surname>Ray</surname><given-names>A</given-names></name><name><surname>Cappannini</surname><given-names>A</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Purta</surname><given-names>E</given-names></name><name><surname>Kurkowska</surname><given-names>M</given-names></name><name><surname>Shirvanizadeh</surname><given-names>N</given-names></name><name><surname>Destefanis</surname><given-names>E</given-names></name><name><surname>Groza</surname><given-names>P</given-names></name><name><surname>Avşar</surname><given-names>G</given-names></name><name><surname>Romitelli</surname><given-names>A</given-names></name><name><surname>Pir</surname><given-names>P</given-names></name><name><surname>Dassi</surname><given-names>E</given-names></name><name><surname>Conticello</surname><given-names>SG</given-names></name><name><surname>Aguilo</surname><given-names>F</given-names></name><name><surname>Bujnicki</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>MODOMICS: a database of RNA modification pathways. 2021 update</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D231</fpage><lpage>D235</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1083</pub-id><pub-id pub-id-type="pmid">34893873</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bubis</surname><given-names>J</given-names></name><name><surname>Martínez</surname><given-names>JC</given-names></name><name><surname>Calabokis</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>J</given-names></name><name><surname>Sanz-Rodríguez</surname><given-names>CE</given-names></name><name><surname>Navas</surname><given-names>V</given-names></name><name><surname>Escalona</surname><given-names>JL</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The gene product of a Trypanosoma equiperdum ortholog of the cAMP-dependent protein kinase regulatory subunit is a monomeric protein that is not capable of binding cyclic nucleotides</article-title><source>Biochimie</source><volume>146</volume><fpage>166</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2017.12.010</pub-id><pub-id pub-id-type="pmid">29288679</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buechler</surname><given-names>YJ</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Regulation-defective mutants of type I cAMP-dependent protein kinase: consequences of replacing arginine 94 and arginine 95</article-title><source>The Journal of Biological Chemistry</source><volume>268</volume><fpage>16495</fpage><lpage>16503</lpage><pub-id pub-id-type="pmid">8393867</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buxton</surname><given-names>IL</given-names></name><name><surname>Brunton</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes</article-title><source>The Journal of Biological Chemistry</source><volume>258</volume><fpage>10233</fpage><lpage>10239</lpage><pub-id pub-id-type="pmid">6309796</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byun</surname><given-names>JA</given-names></name><name><surname>Akimoto</surname><given-names>M</given-names></name><name><surname>VanSchouwen</surname><given-names>B</given-names></name><name><surname>Lazarou</surname><given-names>TS</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Melacini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Allosteric pluripotency as revealed by protein kinase A</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eabb1250</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abb1250</pub-id><pub-id pub-id-type="pmid">32596469</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byun</surname><given-names>JA</given-names></name><name><surname>Van</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Henning</surname><given-names>P</given-names></name><name><surname>Franz</surname><given-names>E</given-names></name><name><surname>Akimoto</surname><given-names>M</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Melacini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Mechanism of allosteric inhibition in the <italic>Plasmodium falciparum</italic> cGMP-dependent protein kinase</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>8480</fpage><lpage>8491</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013070</pub-id><pub-id pub-id-type="pmid">32317283</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byun</surname><given-names>JA</given-names></name><name><surname>VanSchouwen</surname><given-names>B</given-names></name><name><surname>Akimoto</surname><given-names>M</given-names></name><name><surname>Melacini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020c</year><article-title>Allosteric inhibition explained through conformational ensembles sampling distinct “mixed” states</article-title><source>Computational and Structural Biotechnology Journal</source><volume>18</volume><fpage>3803</fpage><lpage>3818</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2020.10.026</pub-id><pub-id pub-id-type="pmid">33335680</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canaves</surname><given-names>JM</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Classification and phylogenetic analysis of the cAMP-dependent protein kinase regulatory subunit family</article-title><source>Journal of Molecular Evolution</source><volume>54</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1007/s00239-001-0013-1</pub-id><pub-id pub-id-type="pmid">11734894</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cayla</surname><given-names>M</given-names></name><name><surname>Nievas</surname><given-names>YR</given-names></name><name><surname>Matthews</surname><given-names>KR</given-names></name><name><surname>Mottram</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Distinguishing functions of trypanosomatid protein kinases</article-title><source>Trends in Parasitology</source><volume>38</volume><fpage>950</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2022.08.009</pub-id><pub-id pub-id-type="pmid">36075845</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho-Chung</surname><given-names>YS</given-names></name><name><surname>Clair</surname><given-names>T</given-names></name><name><surname>Tagliaferri</surname><given-names>P</given-names></name><name><surname>Ally</surname><given-names>S</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name><name><surname>Neckers</surname><given-names>L</given-names></name><name><surname>Avery</surname><given-names>TL</given-names></name><name><surname>Crabtree</surname><given-names>GW</given-names></name><name><surname>Robins</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation</article-title><source>Cancer Investigation</source><volume>7</volume><fpage>161</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.3109/07357908909038282</pub-id><pub-id pub-id-type="pmid">2551468</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>WH</given-names></name><name><surname>Kronstad</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The cAMP/protein kinase A signaling pathway in pathogenic basidiomycete fungi: Connections with iron homeostasis</article-title><source>Journal of Microbiology</source><volume>53</volume><fpage>579</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1007/s12275-015-5247-5</pub-id><pub-id pub-id-type="pmid">26231374</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbin</surname><given-names>JD</given-names></name><name><surname>Ogreid</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>JP</given-names></name><name><surname>Suva</surname><given-names>RH</given-names></name><name><surname>Jastorff</surname><given-names>B</given-names></name><name><surname>Døskeland</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Studies of cGMP analog specificity and function of the two intrasubunit binding sites of cGMP-dependent protein kinase</article-title><source>The Journal of Biological Chemistry</source><volume>261</volume><fpage>1208</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">3003061</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>AP</given-names></name><name><surname>Alexander</surname><given-names>SPH</given-names></name><name><surname>Sharman</surname><given-names>JL</given-names></name><name><surname>Pawson</surname><given-names>AJ</given-names></name><name><surname>Benson</surname><given-names>HE</given-names></name><name><surname>Monaghan</surname><given-names>AE</given-names></name><name><surname>Liew</surname><given-names>WC</given-names></name><name><surname>Mpamhanga</surname><given-names>CP</given-names></name><name><surname>Bonner</surname><given-names>TI</given-names></name><name><surname>Neubig</surname><given-names>RR</given-names></name><name><surname>Pin</surname><given-names>JP</given-names></name><name><surname>Spedding</surname><given-names>M</given-names></name><name><surname>Harmar</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>International union of basic and clinical pharmacology: LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands</article-title><source>Pharmacological Reviews</source><volume>65</volume><fpage>967</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1124/pr.112.007179</pub-id><pub-id pub-id-type="pmid">23686350</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>DR</given-names></name><name><surname>Segal</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="1971">1971</year><chapter-title>Protein crystallization: Micro techniques involving vapor diffusion</chapter-title><person-group person-group-type="editor"><name><surname>Davies</surname><given-names>DR</given-names></name></person-group><source>Methods in Enzymology</source><publisher-name>Elsevier</publisher-name><fpage>266</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/0076-6879(71)22027-9</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diller</surname><given-names>TC</given-names></name><name><surname>Xuong</surname><given-names>NH</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Molecular basis for regulatory subunit diversity in cAMP-dependent protein kinase: crystal structure of the type II beta regulatory subunit</article-title><source>Structure</source><volume>9</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/s0969-2126(00)00556-6</pub-id><pub-id pub-id-type="pmid">11342137</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dostmann</surname><given-names>WR</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Genieser</surname><given-names>HG</given-names></name><name><surname>Jastorff</surname><given-names>B</given-names></name><name><surname>Døskeland</surname><given-names>SO</given-names></name><name><surname>Ogreid</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3’,5’-cyclic phosphorothioates</article-title><source>The Journal of Biological Chemistry</source><volume>265</volume><fpage>10484</fpage><lpage>10491</lpage><pub-id pub-id-type="pmid">2162349</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dostmann</surname><given-names>WR</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Identifying the molecular switches that determine whether (Rp)-cAMPS functions as an antagonist or an agonist in the activation of cAMP-dependent protein kinase I</article-title><source>Biochemistry</source><volume>30</volume><fpage>8710</fpage><lpage>8716</lpage><pub-id pub-id-type="doi">10.1021/bi00099a032</pub-id><pub-id pub-id-type="pmid">1653606</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doutch</surname><given-names>J</given-names></name><name><surname>Hough</surname><given-names>MA</given-names></name><name><surname>Hasnain</surname><given-names>SS</given-names></name><name><surname>Strange</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Challenges of sulfur SAD phasing as a routine method in macromolecular crystallography</article-title><source>Journal of Synchrotron Radiation</source><volume>19</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1107/S0909049511049004</pub-id><pub-id pub-id-type="pmid">22186640</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunin-Horkawicz</surname><given-names>S</given-names></name><name><surname>Czerwoniec</surname><given-names>A</given-names></name><name><surname>Gajda</surname><given-names>MJ</given-names></name><name><surname>Feder</surname><given-names>M</given-names></name><name><surname>Grosjean</surname><given-names>H</given-names></name><name><surname>Bujnicki</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>MODOMICS: a database of RNA modification pathways</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>D145</fpage><lpage>D149</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj084</pub-id><pub-id pub-id-type="pmid">16381833</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of Coot</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friesner</surname><given-names>RA</given-names></name><name><surname>Banks</surname><given-names>JL</given-names></name><name><surname>Murphy</surname><given-names>RB</given-names></name><name><surname>Halgren</surname><given-names>TA</given-names></name><name><surname>Klicic</surname><given-names>JJ</given-names></name><name><surname>Mainz</surname><given-names>DT</given-names></name><name><surname>Repasky</surname><given-names>MP</given-names></name><name><surname>Knoll</surname><given-names>EH</given-names></name><name><surname>Shelley</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>JK</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name><name><surname>Francis</surname><given-names>P</given-names></name><name><surname>Shenkin</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</article-title><source>Journal of Medicinal Chemistry</source><volume>47</volume><fpage>1739</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1021/jm0306430</pub-id><pub-id pub-id-type="pmid">15027865</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gausdal</surname><given-names>G</given-names></name><name><surname>Wergeland</surname><given-names>A</given-names></name><name><surname>Skavland</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>E</given-names></name><name><surname>Pendino</surname><given-names>F</given-names></name><name><surname>Rouhee</surname><given-names>N</given-names></name><name><surname>McCormack</surname><given-names>E</given-names></name><name><surname>Herfindal</surname><given-names>L</given-names></name><name><surname>Kleppe</surname><given-names>R</given-names></name><name><surname>Havemann</surname><given-names>U</given-names></name><name><surname>Schwede</surname><given-names>F</given-names></name><name><surname>Bruserud</surname><given-names>O</given-names></name><name><surname>Gjertsen</surname><given-names>BT</given-names></name><name><surname>Lanotte</surname><given-names>M</given-names></name><name><surname>Ségal-Bendirdjian</surname><given-names>E</given-names></name><name><surname>Døskeland</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis</article-title><source>Cell Death &amp; Disease</source><volume>4</volume><elocation-id>e516</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.39</pub-id><pub-id pub-id-type="pmid">23449452</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginger</surname><given-names>ML</given-names></name><name><surname>Portman</surname><given-names>N</given-names></name><name><surname>McKean</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Swimming with protists: perception, motility and flagellum assembly</article-title><source>Nature Reviews. Microbiology</source><volume>6</volume><fpage>838</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2009</pub-id><pub-id pub-id-type="pmid">18923411</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenfield</surname><given-names>N</given-names></name><name><surname>Fasman</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>Computed circular dichroism spectra for the evaluation of protein conformation</article-title><source>Biochemistry</source><volume>8</volume><fpage>4108</fpage><lpage>4116</lpage><pub-id pub-id-type="doi">10.1021/bi00838a031</pub-id><pub-id pub-id-type="pmid">5346390</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>JC</given-names></name><name><surname>Pool</surname><given-names>EH</given-names></name><name><surname>Bruystens</surname><given-names>JGH</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>DR</given-names></name><name><surname>Palay</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Choi</surname><given-names>JLC</given-names></name><name><surname>Lee</surname><given-names>HN</given-names></name><name><surname>Strack</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Molecular determinants and signaling effects of PKA RIα Phase Separation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2023.12.10.570836</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haste</surname><given-names>NM</given-names></name><name><surname>Talabani</surname><given-names>H</given-names></name><name><surname>Doo</surname><given-names>A</given-names></name><name><surname>Merckx</surname><given-names>A</given-names></name><name><surname>Langsley</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Exploring the <italic>Plasmodium falciparum</italic> cyclic-adenosine monophosphate (cAMP)-dependent protein kinase (PfPKA) as a therapeutic target</article-title><source>Microbes and Infection</source><volume>14</volume><fpage>838</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2012.05.004</pub-id><pub-id pub-id-type="pmid">22626931</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastie</surname><given-names>CJ</given-names></name><name><surname>McLauchlan</surname><given-names>HJ</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Assay of protein kinases using radiolabeled ATP: a protocol</article-title><source>Nature Protocols</source><volume>1</volume><fpage>968</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.149</pub-id><pub-id pub-id-type="pmid">17406331</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haushalter</surname><given-names>KJ</given-names></name><name><surname>Casteel</surname><given-names>DE</given-names></name><name><surname>Raffeiner</surname><given-names>A</given-names></name><name><surname>Stefan</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>HH</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phosphorylation of protein kinase A (PKA) regulatory subunit RIα by protein kinase G (PKG) primes PKA for catalytic activity in cells</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>4411</fpage><lpage>4421</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.809988</pub-id><pub-id pub-id-type="pmid">29378851</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Dostmann</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Active site mutations define the pathway for the cooperative activation of cAMP-dependent protein kinase</article-title><source>Biochemistry</source><volume>35</volume><fpage>2934</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.1021/bi951647c</pub-id><pub-id pub-id-type="pmid">8608131</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hitz</surname><given-names>E</given-names></name><name><surname>Wiedemar</surname><given-names>N</given-names></name><name><surname>Passecker</surname><given-names>A</given-names></name><name><surname>Graça</surname><given-names>BAS</given-names></name><name><surname>Scheurer</surname><given-names>C</given-names></name><name><surname>Wittlin</surname><given-names>S</given-names></name><name><surname>Brancucci</surname><given-names>NMB</given-names></name><name><surname>Vakonakis</surname><given-names>I</given-names></name><name><surname>Mäser</surname><given-names>P</given-names></name><name><surname>Voss</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The 3-phosphoinositide-dependent protein kinase 1 is an essential upstream activator of protein kinase A in malaria parasites</article-title><source>PLOS Biology</source><volume>19</volume><elocation-id>e3001483</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001483</pub-id><pub-id pub-id-type="pmid">34879056</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>SN</given-names></name><name><surname>Hunt</surname><given-names>HD</given-names></name><name><surname>Horton</surname><given-names>RM</given-names></name><name><surname>Pullen</surname><given-names>JK</given-names></name><name><surname>Pease</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Site-directed mutagenesis by overlap extension using the polymerase chain reaction</article-title><source>Gene</source><volume>77</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(89)90358-2</pub-id><pub-id pub-id-type="pmid">2744487</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Weiss</surname><given-names>LM</given-names></name><name><surname>Nagajyothi</surname><given-names>F</given-names></name><name><surname>Tanowitz</surname><given-names>HB</given-names></name><name><surname>Wittner</surname><given-names>M</given-names></name><name><surname>Orr</surname><given-names>GA</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Molecular cloning and characterization of the protein kinase A regulatory subunit of Trypanosoma cruzi</article-title><source>Molecular and Biochemical Parasitology</source><volume>149</volume><fpage>242</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.molbiopara.2006.05.008</pub-id><pub-id pub-id-type="pmid">16815565</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>GY</given-names></name><name><surname>Gerlits</surname><given-names>OO</given-names></name><name><surname>Blakeley</surname><given-names>MP</given-names></name><name><surname>Sankaran</surname><given-names>B</given-names></name><name><surname>Kovalevsky</surname><given-names>AY</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>Neutron diffraction reveals hydrogen bonds critical for cGMP-selective activation: insights for cGMP-dependent protein kinase agonist design</article-title><source>Biochemistry</source><volume>53</volume><fpage>6725</fpage><lpage>6727</lpage><pub-id pub-id-type="doi">10.1021/bi501012v</pub-id><pub-id pub-id-type="pmid">25271401</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>GY</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Reger</surname><given-names>AS</given-names></name><name><surname>Lorenz</surname><given-names>R</given-names></name><name><surname>Moon</surname><given-names>EW</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Casteel</surname><given-names>DE</given-names></name><name><surname>Bertinetti</surname><given-names>D</given-names></name><name><surname>Vanschouwen</surname><given-names>B</given-names></name><name><surname>Selvaratnam</surname><given-names>R</given-names></name><name><surname>Pflugrath</surname><given-names>JW</given-names></name><name><surname>Sankaran</surname><given-names>B</given-names></name><name><surname>Melacini</surname><given-names>G</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Structural basis for cyclic-nucleotide selectivity and cGMP-selective activation of PKG I</article-title><source>Structure</source><volume>22</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.str.2013.09.021</pub-id><pub-id pub-id-type="pmid">24239458</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huseby</surname><given-names>S</given-names></name><name><surname>Gausdal</surname><given-names>G</given-names></name><name><surname>Keen</surname><given-names>TJ</given-names></name><name><surname>Kjærland</surname><given-names>E</given-names></name><name><surname>Krakstad</surname><given-names>C</given-names></name><name><surname>Myhren</surname><given-names>L</given-names></name><name><surname>Brønstad</surname><given-names>K</given-names></name><name><surname>Kunick</surname><given-names>C</given-names></name><name><surname>Schwede</surname><given-names>F</given-names></name><name><surname>Genieser</surname><given-names>H-G</given-names></name><name><surname>Kleppe</surname><given-names>R</given-names></name><name><surname>Døskeland</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription</article-title><source>Cell Death &amp; Disease</source><volume>2</volume><elocation-id>e237</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2011.124</pub-id><pub-id pub-id-type="pmid">22158476</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Marq</surname><given-names>JB</given-names></name><name><surname>Bisio</surname><given-names>H</given-names></name><name><surname>Jacot</surname><given-names>D</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Choudhary</surname><given-names>J</given-names></name><name><surname>Brochet</surname><given-names>M</given-names></name><name><surname>Soldati-Favre</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Crosstalk between PKA and PKG controls pH-dependent host cell egress of <italic>Toxoplasma gondii</italic></article-title><source>The EMBO Journal</source><volume>36</volume><fpage>3250</fpage><lpage>3267</lpage><pub-id pub-id-type="doi">10.15252/embj.201796794</pub-id><pub-id pub-id-type="pmid">29030485</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>XSCALE</article-title><source>International Tables for Crystallography</source><volume>Vol. F., chap. 11.6.3</volume><fpage>308</fpage><lpage>309</lpage></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannan</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Anand</surname><given-names>GS</given-names></name><name><surname>Yooseph</surname><given-names>S</given-names></name><name><surname>Neuwald</surname><given-names>AF</given-names></name><name><surname>Venter</surname><given-names>JC</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Evolution of allostery in the cyclic nucleotide binding module</article-title><source>Genome Biology</source><volume>8</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2007-8-12-r264</pub-id><pub-id pub-id-type="pmid">18076763</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khamina</surname><given-names>M</given-names></name><name><surname>Martinez Pomier</surname><given-names>K</given-names></name><name><surname>Akimoto</surname><given-names>M</given-names></name><name><surname>VanSchouwen</surname><given-names>B</given-names></name><name><surname>Melacini</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Non-canonical allostery in cyclic nucleotide dependent kinases</article-title><source>Journal of Molecular Biology</source><volume>434</volume><elocation-id>167584</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2022.167584</pub-id><pub-id pub-id-type="pmid">35427632</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Xuong</surname><given-names>NH</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA</article-title><source>Science</source><volume>307</volume><fpage>690</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1126/science.1104607</pub-id><pub-id pub-id-type="pmid">15692043</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>CY</given-names></name><name><surname>Saldanha</surname><given-names>SA</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation</article-title><source>Cell</source><volume>130</volume><fpage>1032</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.07.018</pub-id><pub-id pub-id-type="pmid">17889648</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Achcar</surname><given-names>F</given-names></name><name><surname>Breitling</surname><given-names>R</given-names></name><name><surname>Burgess</surname><given-names>KE</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LC-MS-based absolute metabolite quantification: application to metabolic flux measurement in trypanosomes</article-title><source>Metabolomics</source><volume>11</volume><fpage>1721</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1007/s11306-015-0827-2</pub-id><pub-id pub-id-type="pmid">26491423</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>KT</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Cheong</surname><given-names>E</given-names></name><name><surname>Bahn</surname><given-names>YS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Adenylyl cyclase and protein kinase A play redundant and distinct roles in growth, differentiation, antifungal drug resistance, and pathogenicity of <italic>Candida auris</italic></article-title><source>mBio</source><volume>12</volume><elocation-id>e0272921</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02729-21</pub-id><pub-id pub-id-type="pmid">34663094</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cyclic nucleotide selectivity of protein kinase G isozymes</article-title><source>Protein Science</source><volume>30</volume><fpage>316</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1002/pro.4008</pub-id><pub-id pub-id-type="pmid">33271627</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurokawa</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Iwanaga</surname><given-names>T</given-names></name><name><surname>Sugi</surname><given-names>T</given-names></name><name><surname>Sudo</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>Takemae</surname><given-names>H</given-names></name><name><surname>Recuenco</surname><given-names>FC</given-names></name><name><surname>Horimoto</surname><given-names>T</given-names></name><name><surname>Akashi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Identification of <italic>Toxoplasma gondii</italic> cAMP dependent protein kinase and its role in the tachyzoite growth</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e22492</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0022492</pub-id><pub-id pub-id-type="pmid">21799871</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Lodder</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Patriarchi</surname><given-names>T</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cell-type-specific asynchronous modulation of PKA by dopamine in learning</article-title><source>Nature</source><volume>590</volume><fpage>451</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-03050-5</pub-id><pub-id pub-id-type="pmid">33361810</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebschner</surname><given-names>D</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Baker</surname><given-names>ML</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Hintze</surname><given-names>B</given-names></name><name><surname>Hung</surname><given-names>LW</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>RD</given-names></name><name><surname>Poon</surname><given-names>BK</given-names></name><name><surname>Prisant</surname><given-names>MG</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Sammito</surname><given-names>MD</given-names></name><name><surname>Sobolev</surname><given-names>OV</given-names></name><name><surname>Stockwell</surname><given-names>DH</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Urzhumtsev</surname><given-names>AG</given-names></name><name><surname>Videau</surname><given-names>LL</given-names></name><name><surname>Williams</surname><given-names>CJ</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</article-title><source>Acta Crystallographica. Section D, Structural Biology</source><volume>75</volume><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id><pub-id pub-id-type="pmid">31588918</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Littler</surname><given-names>DR</given-names></name><name><surname>Bullen</surname><given-names>HE</given-names></name><name><surname>Harvey</surname><given-names>KL</given-names></name><name><surname>Beddoe</surname><given-names>T</given-names></name><name><surname>Crabb</surname><given-names>BS</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Gilson</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Disrupting the allosteric interaction between the <italic>Plasmodium falciparum</italic> cAMP-dependent kinase and its regulatory subunit</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>25375</fpage><lpage>25386</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.750174</pub-id><pub-id pub-id-type="pmid">27738107</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>López-Palacios</surname><given-names>TP</given-names></name><name><surname>Andersen</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Kinase regulation by liquid-liquid phase separation</article-title><source>Trends in Cell Biology</source><volume>33</volume><fpage>649</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2022.11.009</pub-id><pub-id pub-id-type="pmid">36528418</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>R</given-names></name><name><surname>Bertinetti</surname><given-names>D</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>cAMP-Dependent Protein Kinase and cGMP-dependent protein kinase as cyclic nucleotide effectors</article-title><source>Experimental Pharmacology</source><volume>238</volume><fpage>105</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1007/164_2015_36</pub-id><pub-id pub-id-type="pmid">27885524</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>R</given-names></name><name><surname>Moon</surname><given-names>EW</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Schmidt</surname><given-names>SH</given-names></name><name><surname>Sankaran</surname><given-names>B</given-names></name><name><surname>Pavlidis</surname><given-names>IV</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Mutations of PKA cyclic nucleotide-binding domains reveal novel aspects of cyclic nucleotide selectivity</article-title><source>The Biochemical Journal</source><volume>474</volume><fpage>2389</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1042/BCJ20160969</pub-id><pub-id pub-id-type="pmid">28583991</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmstrom</surname><given-names>RD</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Amaro</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Allostery through the computational microscope: cAMP activation of a canonical signalling domain</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7588</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8588</pub-id><pub-id pub-id-type="pmid">26145448</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>25 years of African trypanosome research: From description to molecular dissection and new drug discovery</article-title><source>Molecular and Biochemical Parasitology</source><volume>200</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.molbiopara.2015.01.006</pub-id><pub-id pub-id-type="pmid">25736427</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Trypanosome Signaling-Quorum Sensing</article-title><source>Annual Review of Microbiology</source><volume>75</volume><fpage>495</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-020321-115246</pub-id><pub-id pub-id-type="pmid">34348028</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Solving structures of protein complexes by molecular replacement with Phaser</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>63</volume><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1107/S0907444906045975</pub-id><pub-id pub-id-type="pmid">17164524</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Kennedy</surname><given-names>EJ</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Hui</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Langsley</surname><given-names>G</given-names></name><name><surname>Kannan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural and evolutionary divergence of cyclic nucleotide binding domains in eukaryotic pathogens: Implications for drug design</article-title><source>Biochimica et Biophysica Acta</source><volume>1854</volume><fpage>1575</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2015.03.012</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moll</surname><given-names>D</given-names></name><name><surname>Schweinsberg</surname><given-names>S</given-names></name><name><surname>Hammann</surname><given-names>C</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Comparative thermodynamic analysis of cyclic nucleotide binding to protein kinase A</article-title><source>Biological Chemistry</source><volume>388</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1515/BC.2007.018</pub-id><pub-id pub-id-type="pmid">17261079</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mony</surname><given-names>BM</given-names></name><name><surname>MacGregor</surname><given-names>P</given-names></name><name><surname>Ivens</surname><given-names>A</given-names></name><name><surname>Rojas</surname><given-names>F</given-names></name><name><surname>Cowton</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name><name><surname>Matthews</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-wide dissection of the quorum sensing signalling pathway in <italic>Trypanosoma brucei</italic></article-title><source>Nature</source><volume>505</volume><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/nature12864</pub-id><pub-id pub-id-type="pmid">24336212</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musheshe</surname><given-names>N</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Zaccolo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>cAMP: from long-range second messenger to nanodomain signalling</article-title><source>Trends in Pharmacological Sciences</source><volume>39</volume><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2017.11.006</pub-id><pub-id pub-id-type="pmid">29289379</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niesen</surname><given-names>FH</given-names></name><name><surname>Berglund</surname><given-names>H</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</article-title><source>Nature Protocols</source><volume>2</volume><fpage>2212</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.321</pub-id><pub-id pub-id-type="pmid">17853878</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberholzer</surname><given-names>M</given-names></name><name><surname>Lopez</surname><given-names>MA</given-names></name><name><surname>McLelland</surname><given-names>BT</given-names></name><name><surname>Hill</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Social motility in african trypanosomes</article-title><source>PLOS Pathogens</source><volume>6</volume><elocation-id>e1000739</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000739</pub-id><pub-id pub-id-type="pmid">20126443</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberholzer</surname><given-names>M</given-names></name><name><surname>Langousis</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Saada</surname><given-names>EA</given-names></name><name><surname>Shimogawa</surname><given-names>MM</given-names></name><name><surname>Jonsson</surname><given-names>ZO</given-names></name><name><surname>Nguyen</surname><given-names>SM</given-names></name><name><surname>Wohlschlegel</surname><given-names>JA</given-names></name><name><surname>Hill</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Independent analysis of the flagellum surface and matrix proteomes provides insight into flagellum signaling in mammalian-infectious <italic>Trypanosoma brucei</italic></article-title><source>Molecular &amp; Cellular Proteomics</source><volume>10</volume><elocation-id>M111</elocation-id><pub-id pub-id-type="doi">10.1074/mcp.M111.010538</pub-id><pub-id pub-id-type="pmid">21685506</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogreid</surname><given-names>D</given-names></name><name><surname>Ekanger</surname><given-names>R</given-names></name><name><surname>Suva</surname><given-names>RH</given-names></name><name><surname>Miller</surname><given-names>JP</given-names></name><name><surname>Døskeland</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Comparison of the two classes of binding sites (A and B) of type I and type II cyclic-AMP-dependent protein kinases by using cyclic nucleotide analogs</article-title><source>European Journal of Biochemistry</source><volume>181</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1989.tb14689.x</pub-id><pub-id pub-id-type="pmid">2540965</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>CP</given-names></name><name><surname>Bastin</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>More than meets the eye: understanding <italic>Trypanosoma brucei</italic> morphology in the tsetse</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>3</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2013.00071</pub-id><pub-id pub-id-type="pmid">24312899</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paolocci</surname><given-names>E</given-names></name><name><surname>Zaccolo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Compartmentalised cAMP signalling in the primary cilium</article-title><source>Frontiers in Physiology</source><volume>14</volume><elocation-id>1187134</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2023.1187134</pub-id><pub-id pub-id-type="pmid">37256063</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passner</surname><given-names>JM</given-names></name><name><surname>Steitz</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The structure of a CAP-DNA complex having two cAMP molecules bound to each monomer</article-title><source>PNAS</source><volume>94</volume><fpage>2843</fpage><lpage>2847</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.7.2843</pub-id><pub-id pub-id-type="pmid">9096308</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrin</surname><given-names>AJ</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Flueck</surname><given-names>C</given-names></name><name><surname>Blackman</surname><given-names>MJ</given-names></name><name><surname>Baker</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>cAMP signalling and its role in host cell invasion by malaria parasites</article-title><source>Current Opinion in Microbiology</source><volume>58</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2020.09.003</pub-id><pub-id pub-id-type="pmid">33032143</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehmann</surname><given-names>H</given-names></name><name><surname>Wittinghofer</surname><given-names>A</given-names></name><name><surname>Bos</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Capturing cyclic nucleotides in action: snapshots from crystallographic studies</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>8</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/nrm2082</pub-id><pub-id pub-id-type="pmid">17183361</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rico-Jiménez</surname><given-names>M</given-names></name><name><surname>Ceballos-Pérez</surname><given-names>G</given-names></name><name><surname>Gómez-Liñán</surname><given-names>C</given-names></name><name><surname>Estévez</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An RNA-binding protein complex regulates the purine-dependent expression of a nucleobase transporter in trypanosomes</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>3814</fpage><lpage>3825</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab181</pub-id><pub-id pub-id-type="pmid">33744953</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinaldi</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Ralston</surname><given-names>CY</given-names></name><name><surname>Sankaran</surname><given-names>B</given-names></name><name><surname>Moreno</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structure of yeast regulatory subunit: a glimpse into the evolution of PKA signaling</article-title><source>Structure</source><volume>18</volume><fpage>1471</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1016/j.str.2010.08.013</pub-id><pub-id pub-id-type="pmid">21070946</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmon</surname><given-names>D</given-names></name><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Krumbholz</surname><given-names>C</given-names></name><name><surname>Kador</surname><given-names>M</given-names></name><name><surname>Gossmann</surname><given-names>JA</given-names></name><name><surname>Uzureau</surname><given-names>P</given-names></name><name><surname>Pays</surname><given-names>E</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>Cytokinesis of <italic>Trypanosoma brucei</italic> bloodstream forms depends on expression of adenylyl cyclases of the ESAG4 or ESAG4-like subfamily</article-title><source>Molecular Microbiology</source><volume>84</volume><fpage>225</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2012.08013.x</pub-id><pub-id pub-id-type="pmid">22340731</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmon</surname><given-names>D</given-names></name><name><surname>Vanwalleghem</surname><given-names>G</given-names></name><name><surname>Morias</surname><given-names>Y</given-names></name><name><surname>Denoeud</surname><given-names>J</given-names></name><name><surname>Krumbholz</surname><given-names>C</given-names></name><name><surname>Lhommé</surname><given-names>F</given-names></name><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Kador</surname><given-names>M</given-names></name><name><surname>Gossmann</surname><given-names>J</given-names></name><name><surname>Dias</surname><given-names>FBS</given-names></name><name><surname>De Muylder</surname><given-names>G</given-names></name><name><surname>Uzureau</surname><given-names>P</given-names></name><name><surname>Magez</surname><given-names>S</given-names></name><name><surname>Moser</surname><given-names>M</given-names></name><name><surname>De Baetselier</surname><given-names>P</given-names></name><name><surname>Van Den Abbeele</surname><given-names>J</given-names></name><name><surname>Beschin</surname><given-names>A</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name><name><surname>Pays</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>Adenylate cyclases of <italic>Trypanosoma brucei</italic> inhibit the innate immune response of the host</article-title><source>Science</source><volume>337</volume><fpage>463</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1126/science.1222753</pub-id><pub-id pub-id-type="pmid">22700656</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenk</surname><given-names>R</given-names></name><name><surname>Bachmaier</surname><given-names>S</given-names></name><name><surname>Bringaud</surname><given-names>F</given-names></name><name><surname>Boshart</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efficient flavinylation of glycosomal fumarate reductase by its own ApbE domain in <italic>Trypanosoma brucei</italic></article-title><source>The FEBS Journal</source><volume>288</volume><fpage>5430</fpage><lpage>5445</lpage><pub-id pub-id-type="doi">10.1111/febs.15812</pub-id><pub-id pub-id-type="pmid">33755328</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwede</surname><given-names>F</given-names></name><name><surname>Maronde</surname><given-names>E</given-names></name><name><surname>Genieser</surname><given-names>H</given-names></name><name><surname>Jastorff</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cyclic nucleotide analogs as biochemical tools and prospective drugs</article-title><source>Pharmacology &amp; Therapeutics</source><volume>87</volume><fpage>199</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/s0163-7258(00)00051-6</pub-id><pub-id pub-id-type="pmid">11008001</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabb</surname><given-names>JB</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Corbin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>One amino acid change produces a high affinity cGMP-binding site in cAMP-dependent protein kinase</article-title><source>The Journal of Biological Chemistry</source><volume>265</volume><fpage>16031</fpage><lpage>16034</lpage><pub-id pub-id-type="pmid">2168874</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabb</surname><given-names>JB</given-names></name><name><surname>Buzzeo</surname><given-names>BD</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Corbin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Mutating protein kinase cAMP-binding sites into cGMP-binding sites: mechanism of cGMP selectivity</article-title><source>The Journal of Biological Chemistry</source><volume>266</volume><fpage>24320</fpage><lpage>24326</lpage><pub-id pub-id-type="pmid">1662209</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>S</given-names></name><name><surname>Knüsel</surname><given-names>S</given-names></name><name><surname>Abbühl</surname><given-names>D</given-names></name><name><surname>Naguleswaran</surname><given-names>A</given-names></name><name><surname>Etzensperger</surname><given-names>R</given-names></name><name><surname>Benninger</surname><given-names>M</given-names></name><name><surname>Roditi</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Cyclic AMP signalling and glucose metabolism mediate pH taxis by African trypanosomes</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>603</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28293-w</pub-id><pub-id pub-id-type="pmid">35105902</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Dostmann</surname><given-names>WR</given-names></name><name><surname>Herberg</surname><given-names>FW</given-names></name><name><surname>Durick</surname><given-names>K</given-names></name><name><surname>Xuong</surname><given-names>NH</given-names></name><name><surname>Ten Eyck</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Varughese</surname><given-names>KI</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains</article-title><source>Science</source><volume>269</volume><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1126/science.7638597</pub-id><pub-id pub-id-type="pmid">7638597</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Ilouz</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Assembly of allosteric macromolecular switches: lessons from PKA</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>13</volume><fpage>646</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/nrm3432</pub-id><pub-id pub-id-type="pmid">22992589</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>SS</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Bruystens</surname><given-names>JGH</given-names></name><name><surname>Del Rio</surname><given-names>JC</given-names></name><name><surname>Lu</surname><given-names>T-W</given-names></name><name><surname>Kornev</surname><given-names>AP</given-names></name><name><surname>Ten Eyck</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>From structure to the dynamic regulation of A molecular switch: A journey over 3 decades</article-title><source>The Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100746</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100746</pub-id><pub-id pub-id-type="pmid">33957122</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toh</surname><given-names>JY</given-names></name><name><surname>Nkouawa</surname><given-names>A</given-names></name><name><surname>Sánchez</surname><given-names>SR</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Kolev</surname><given-names>NG</given-names></name><name><surname>Tschudi</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identification of positive and negative regulators in the stepwise developmental progression towards infectivity in <italic>Trypanosoma brucei</italic></article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>5755</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-85225-2</pub-id><pub-id pub-id-type="pmid">33707699</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traube</surname><given-names>FR</given-names></name><name><surname>Schiffers</surname><given-names>S</given-names></name><name><surname>Iwan</surname><given-names>K</given-names></name><name><surname>Kellner</surname><given-names>S</given-names></name><name><surname>Spada</surname><given-names>F</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Carell</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Isotope-dilution mass spectrometry for exact quantification of noncanonical DNA nucleosides</article-title><source>Nature Protocols</source><volume>14</volume><fpage>283</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/s41596-018-0094-6</pub-id><pub-id pub-id-type="pmid">30559375</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsigankov</surname><given-names>P</given-names></name><name><surname>Gherardini</surname><given-names>PF</given-names></name><name><surname>Helmer-Citterich</surname><given-names>M</given-names></name><name><surname>Späth</surname><given-names>GF</given-names></name><name><surname>Myler</surname><given-names>PJ</given-names></name><name><surname>Zilberstein</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation dynamics of Leishmania differentiation: deconvoluting signals and identifying phosphorylation trends</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.037705</pub-id><pub-id pub-id-type="pmid">24741111</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uboldi</surname><given-names>AD</given-names></name><name><surname>Wilde</surname><given-names>ML</given-names></name><name><surname>McRae</surname><given-names>EA</given-names></name><name><surname>Stewart</surname><given-names>RJ</given-names></name><name><surname>Dagley</surname><given-names>LF</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Katris</surname><given-names>NJ</given-names></name><name><surname>Hapuarachchi</surname><given-names>SV</given-names></name><name><surname>Coffey</surname><given-names>MJ</given-names></name><name><surname>Lehane</surname><given-names>AM</given-names></name><name><surname>Botte</surname><given-names>CY</given-names></name><name><surname>Waller</surname><given-names>RF</given-names></name><name><surname>Webb</surname><given-names>AI</given-names></name><name><surname>McConville</surname><given-names>MJ</given-names></name><name><surname>Tonkin</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Protein kinase A negatively regulates Ca2+ signalling in <italic>Toxoplasma gondii</italic></article-title><source>PLOS Biology</source><volume>16</volume><elocation-id>e2005642</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2005642</pub-id><pub-id pub-id-type="pmid">30208022</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbaniak</surname><given-names>MD</given-names></name><name><surname>Martin</surname><given-names>DMA</given-names></name><name><surname>Ferguson</surname><given-names>MAJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Global quantitative SILAC phosphoproteomics reveals differential phosphorylation is widespread between the procyclic and bloodstream form lifecycle stages of <italic>Trypanosoma brucei</italic></article-title><source>Journal of Proteome Research</source><volume>12</volume><fpage>2233</fpage><lpage>2244</lpage><pub-id pub-id-type="doi">10.1021/pr400086y</pub-id><pub-id pub-id-type="pmid">23485197</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidyanathan</surname><given-names>PP</given-names></name><name><surname>Zinshteyn</surname><given-names>B</given-names></name><name><surname>Thompson</surname><given-names>MK</given-names></name><name><surname>Gilbert</surname><given-names>WV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Protein kinase A regulates gene-specific translational adaptation in differentiating yeast</article-title><source>RNA</source><volume>20</volume><fpage>912</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1261/rna.044552.114</pub-id><pub-id pub-id-type="pmid">24759091</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>DA</given-names></name><name><surname>Perkins</surname><given-names>JP</given-names></name><name><surname>Krebs</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="1968">1968</year><article-title>An adenosine 3’,5’-monophosphate-dependant protein kinase from rabbit skeletal muscle</article-title><source>The Journal of Biological Chemistry</source><volume>243</volume><fpage>3763</fpage><lpage>3765</lpage><pub-id pub-id-type="pmid">4298072</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Multiple protein kinases from Trypanosoma gambiense</article-title><source>Hoppe-Seyler’s Zeitschrift Fur Physiologische Chemie</source><volume>359</volume><fpage>601</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1515/bchm.1978.359.1.601</pub-id><pub-id pub-id-type="pmid">208947</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>IT</given-names></name><name><surname>Shabb</surname><given-names>JB</given-names></name><name><surname>Corbin</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Predicted structures of the cGMP binding domains of the cGMP-dependent protein kinase: a key alanine/threonine difference in evolutionary divergence of cAMP and cGMP binding sites</article-title><source>Biochemistry</source><volume>28</volume><fpage>6122</fpage><lpage>6127</lpage><pub-id pub-id-type="doi">10.1021/bi00440a059</pub-id><pub-id pub-id-type="pmid">2550070</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Xuong</surname><given-names>NH</given-names></name><name><surname>Taylor</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>RIalpha subunit of PKA: a cAMP-free structure reveals a hydrophobic capping mechanism for docking cAMP into site B</article-title><source>Structure</source><volume>12</volume><fpage>1057</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1016/j.str.2004.03.022</pub-id><pub-id pub-id-type="pmid">15274925</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaccolo</surname><given-names>M</given-names></name><name><surname>Zerio</surname><given-names>A</given-names></name><name><surname>Lobo</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Subcellular organization of the cAMP signaling pathway</article-title><source>Pharmacological Reviews</source><volume>73</volume><fpage>278</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1124/pharmrev.120.000086</pub-id><pub-id pub-id-type="pmid">33334857</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zagotta</surname><given-names>WN</given-names></name><name><surname>Olivier</surname><given-names>NB</given-names></name><name><surname>Black</surname><given-names>KD</given-names></name><name><surname>Young</surname><given-names>EC</given-names></name><name><surname>Olson</surname><given-names>R</given-names></name><name><surname>Gouaux</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Structural basis for modulation and agonist specificity of HCN pacemaker channels</article-title><source>Nature</source><volume>425</volume><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/nature01922</pub-id><pub-id pub-id-type="pmid">12968185</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91040.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Exceptional</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Landmark</kwd></kwd-group></front-stub><body><p>This <bold>landmark</bold> study sheds light on a long-standing puzzle in Protein kinase A activation in Trypanosoma. Extensive experimental work provides <bold>exceptional</bold> evidence for the conclusions of the work, which represents a significant advancement in our understanding of the molecular mechanism of cyclic nucleotide binding domains. The work is relevant for researchers with interests in kinases and their mechanistic study.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91040.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Cyclic Nucleotide Binding (CNB) domains are pervasive structural components involved in signaling pathways across eukaryotes and prokaryotes. Despite their similar structures, CNB domains exhibit distinct ligand-sensing capabilities. The manuscript offers a thorough and convincing investigation that clarifies numerous puzzling aspects of nucleotide binding in Trypanosoma.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91040.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript clearly shows that Trypanosoma PKA is controlled by nucleoside analogues rather than cyclic nucleotides, which are the primary allosteric effectors of human PKA and PKG. The authors demonstrate that the inosine, guanosine, and adenosine nucleosides bind with high affinity and activate PKA in the tropical pathogens <italic>T. brucei</italic>, <italic>T. cruzi</italic> and Leishmania. The underlying determinants of nucleoside binding and selectivity are dissected by solving the crystal structure of T. cruzi PKAR(200-503) and <italic>T. brucei</italic> PKAR(199-499) bound to inosine at 1.4 Å and 2.1 Å resolution and through comparative mutational analyses. Of particular interest is the identification of a minimal subset of 2-3 residues that controls nucleoside vs. cyclic nucleotide specificity.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91040.3.sa3</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ober</surname><given-names>Veronica Teresa</given-names></name><role specific-use="author">Author</role><aff><institution>Faculty of Biology, Genetics, Ludwig-Maximilian-University Munich</institution><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Githure</surname><given-names>George Boniface</given-names></name><role specific-use="author">Author</role><aff><institution>Faculty of Biology, Genetics, Ludwig-Maximilian-University Munich</institution><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Volpato Santos</surname><given-names>Yuri</given-names></name><role specific-use="author">Author</role><aff><institution>Faculty of Biology, Genetics, Ludwig-Maximilian-University Munich</institution><addr-line><named-content content-type="city">Planegg-Martinsried</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Becker</surname><given-names>Sidney</given-names></name><role specific-use="author">Author</role><aff><institution>Max Planck Institute of Molecular Physiology</institution><addr-line><named-content content-type="city">Dortmund</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Moya Munoz</surname><given-names>Gabriel</given-names></name><role specific-use="author">Author</role><aff><institution>Faculty of Biology, Genetics, Ludwig-Maximilian-University Munich</institution><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Basquin</surname><given-names>Jérôme</given-names></name><role specific-use="author">Author</role><aff><institution>Max Planck Institute of Biochemistry, Martinsried, Germany</institution><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Schwede</surname><given-names>Frank</given-names></name><role specific-use="author">Author</role><aff><institution>BIOLOG Life Science Institute GmbH &amp; Co. KG, Bremen, Germany</institution><addr-line><named-content content-type="city">Bremen</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Lorentzen</surname><given-names>Esben</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark</institution><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff></contrib><contrib contrib-type="author"><name><surname>Boshart</surname><given-names>Michael</given-names></name><role specific-use="author">Author</role><aff><institution>Faculty of Biology, Genetics, Ludwig-Maximilian-University Munich</institution><addr-line><named-content content-type="city">Martinsried</named-content></addr-line><country>Germany</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife assessment</bold></p><p>This landmark study sheds light on a long-standing puzzle of Protein kinase A activation in Trypanosoma. Extensive experimental work provides compelling evidence for the conclusions of the manuscript. It represents a significant advancement in our understanding of the molecular mechanism of Cyclic Nucleotide Binding domains and will be of interest to researchers with interest in kinases and mechanistic studies.</p><p><bold>Public Reviews</bold>:</p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>Cyclic Nucleotide Binding (CNB) domains are pervasive structural components involved in signaling pathways across eukaryotes and prokaryotes. Despite their similar structures, CNB domains exhibit distinct ligand-sensing capabilities. The manuscript offers a thorough and convincing investigation that clarifies numerous puzzling aspects of nucleotide binding in Trypanosoma.</p><p>Strengths:</p><p>One of the strengths of this study is its multifaceted methodology, which includes a range of techniques including crystallography, ITC (Isothermal Titration Calorimetry), fluorimetry, CD (Circular Dichroism) spectroscopy, mass spectrometry, and computational analysis. This interdisciplinary approach not only enhances the depth of the investigation but also offers a robust cross-validation of the results.</p><p>Weaknesses:</p><p>None noticed.</p><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>This manuscript clearly shows that Trypanosoma PKA is controlled by nucleoside analogues rather than cyclic nucleotides, which are the primary allosteric effectors of human PKA and PKG. The authors demonstrate that the inosine, guanosine, and adenosine nucleosides bind with high affinity and activate PKA in the tropical pathogens <italic>T. brucei</italic>, <italic>T. cruzi</italic> and Leishmania. The underlying determinants of nucleoside binding and selectivity are dissected by solving the crystal structure of <italic>T. cruzi</italic> PKAR(200-503) and <italic>T. brucei</italic> PKAR(199-499) bound to inosine at 1.4 Å and 2.1 Å resolution and through comparative mutational analyses. Of particular interest is the identification of a minimal subset of 2-3 residues that controls nucleoside vs. cyclic nucleotide specificity.</p><p>Strengths:</p><p>The significance of this study lies not only in the structure-activity relationships revealed for important targets in several parasite pathogens but also in the understanding of CNB's evolutionary role.</p><p>Weaknesses:</p><p>The main missing piece is the model for activation of the kinetoplastid PKA which remains speculative in the absence of a structure for the trypanosomatid PKA holoenzyme complex. However, this appears to be beyond the scope of this manuscript, which is already quite dense.</p></disp-quote><p>We fully agree that insight into the activation mechanism and its possible deviation from the mammalian paradigm requires a holoenzyme structure revealing the details of R-C interaction. We have attempted Cryo-EM from LEXSY-produced holoenzyme, yet upscaling the purification procedures described in this manuscript have repeatedly failed in spite of numerous protocol changes and optimizations. Much more work is required to achieve this.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Some minor points to consider for enhancing the impact of this interesting manuscript:</p><p>(1) The nucleoside affinities measured are mainly for the regulatory subunits unbound to the kinase domain. How would nucleoside affinities change when the regulatory subunits are bound to the kinase domain, which is presumably the case under resting conditions? An estimation of this change in affinity is important because it more closely relates to the variations in cellular nucleoside concentrations needed for activation.</p></disp-quote><p>This is an important question and we have given an indirect answer in the manuscript, but not very explicit. The EC50 values for kinase activation of the purified holoenzyme complexes are very similar or almost identical to the kD values measured by ITC with free regulatory subunits. By inference, the binding kD for the holoenzyme and for the free R-subunit cannot be very different. In addition, we have recently determined the EC50 for PKA activation in vivo in trypanosomes using a bioluminescence complementation reporter assay. The values fit perfectly to the values obtained with purified holoenzyme (Wu et al. in preparation). A sentence in Results (lines 201-203) has been added.</p><disp-quote content-type="editor-comment"><p>(2) The authors should point out that a major implication of nucleoside vs. cyclic nucleotide activation is in terms of signal termination. If phosphodiesterases (PDEs) are responsible for cAMP/cGMP signal termination, what terminates nucleoside-dependent signaling? Although the answer to this question may not be known at this stage, it is important to highlight this critical implication of the authors' study.</p></disp-quote><p>The mechanism of signal termination is indeed unknown so far. We speculate that some enzymes of the purine salvage pathways are differentially localized in subcellular compartments and thereby able to establish microdomains that enable nucleoside signaling. In addition, PKA subunit phosphorylations/dephosphorylations and/or protein turnover may also regulate signal termination. As an example, free PKAC1 is rapidly degraded upon depletion of the PKAR subunit by RNAi. We have now mentioned signal termination in Discussion and have revised the last part of Discussion (lines 567-602). A possible approach to monitor compartmentalized signaling would be using the FluoSTEPs technology (Tenner et al., Sci. Adv. 2021; 7: eabe4091), but adapting this to the trypanosome system will not be a short-term task.</p></body></sub-article></article>